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I  INTRODUCTION 
 
1 The endothelial barrier and inflammation 
 
The barrier function is the central nature of the endothelium. The maintenance of a 
semi-permeable barrier by the endothelium is particularly important for controlling the 
passage of macromolecules and fluid between the blood and interstitial space and for 
establishing the formation of a transendothelial protein gradient (the colloid osmotic 
gradient) required for tissue fluid homeostasis. The endothelium controls the flux of 
fluid and solutes across the vessel wall by highly regulated transport pathways and 
allows the unimpeded transfer of dissolved gases and ions. The endothelium is 
restrictive to high-molecular-weight substances such as proteins because the tissue 
does usually not consume them rapidly, and there are important reasons to retain 
them in the circulation. And of cause the endothelium strictly regulates transmigration 
of cells into the tissue.1-3 
In general, endothelial transport can be thought of as occurring via paracellular and 
transcellular pathways. In the resting endothelium the transport of proteins and 
liquids occurs via the transcellular pathway.4 In contrast, the paracellular pathway 
plays a pivotal role in the context of inflammation. Intercellular gaps allow the 
passage of plasma proteins including albumin and liquids across the endothelial 
barrier in an unrestricted manner. The loss of barrier function results in tissue 
inflammation and is a hallmark of inflammation-induced diseases such as the acute 
respiratory distress syndrome. The inflammatory mediators thrombin, bradykinin, 
histamine, vascular endothelial growth factor (VEGF), and others disturb the 
organization of interendothelial junctions, and in concequence open the junctional 
barrier.  
2  Inflammation activated endothelium 
 
In recent years, cardiovascular diseases (CVD) like arteriosclerosis or chronic heart 
failure were classified as inflammatory diseases. Chronic inflammation-induced 
activation of the endothelium with its loss of barrier function is an important 
Introduction 
 
2 
parameter in the pathogenesis of these diseases (Figure 1).5-11 There are two central 
markers of endothelial activation: The expression of endothelial cell adhesion 
molecules (CAMs) and endothelial hyperpermeability (EHP), are both hallmarks of 
endothelial inflammation and lead to the opening of the endothelial barrier for the 
passage of macromolecules and leukocytes. Thereby each of these mechanisms 
triggers the inflammatory response, so they enforce each other. The increase in EHP 
leads to edema formation, which can lead for example to hypoxic conditions in the 
surrounding tissue, as well as tissue damage by the activation of the complement 
cascade. This mechanism reinforce the inflammatory response and again leads to 
the progression of CVD.12 The CAM expression at the cell surface of activated 
endothelial cells is vital for transmigration of the leukocytes  through the endothelium 
into the underlying tissue. This again raises endothelial cell activation and is crucial 
for the pathogenesis of atherosclerosis. Vessel occlusion by the formation of 
atherosclerotic plaques triggers chronic inflammation by mechanical stress or areas 
of hypoxic conditions, leading again to the progression of CVD. 
 
Great progress has been made in understanding these processes. To target this 
vicious cycle between endothelial activation and CVD progression is a great 
challenge in drug therapy and new therapeutic options are imperatively needed. CVD 
represent the main cause of death and morbidity in the Western world and is 
projected to be the number one global killer by 2020.13 
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Figure 1: Vicious circle between endothelial activation and CVD progression. An activated 
endothelium leads to increased vascular permeability or CAM expression, both hallmarks of 
inflammation, which promote CVD. CVD itself leads to different responses that promote 
inflammatory endothelial activation. 
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2.1 Signaling of endothelial activation: ICAM-expression 
 
The expression of inter-cellular adhesion molecule-1 (ICAM-1), an inducible cell 
adhesion glycoprotein, is upregulated on the surface of EC after exposure to various 
inflammatory cytokines including tumor necrosis factor-α (TNFα). TNFα induces 
ICAM-1 promotor activities basically via the transcription factor nuclear factor κ-light-
chain-enhancer of activated B cells (NFκB), via activator protein-1 (AP-1), as well as 
by signal transducers and activator of transcription protein-1 (STAT-1) (Figure 2).11 
ICAM-1 mediates the firm adhesion of leukocytes to the endothelium and therefore 
facilitates endothelial transmigration of leukocytes. 
 
 
 
Figure 2: TNFα induces ICAM-1 promotor activity and therefore ICAM-1 expression by activating TNF 
receptor type 1. The crucial step in the underlying signaling cascades is the translocation of 
the transcription factors NFκB, AP-1, and STAT-1 to the nucleus. The upregulation of ICAM-
1 on the cell surface mediates adhesion of leukocytes to the endothelium via Leukocyte 
function Associated Antigen-1 (LFA-1).14  
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2.2  Barrier-disturbing signaling: endothelial hyperpermeability 
 
2.2.1 Signaling of endothelial activation: endothelial hyperpermeability 
 
Inflammation-induced vascular leakage can be initiated by a great variety of stimuli, 
depending on the microenvironment and physiological state. Vascular leakage 
represents a characteristic process for inflammatory endothelial activation and is 
accompanied by reversible activation of the contractile cell machinery (induction of 
contractile forces) and adhesion junction (AJ) disruption (loss of adhesive forces), 
suggesting that the predominant transport pathway is a diffusive one (paracellular 
transport) and the compartimentation is abrogated.15  
There are three key mechanisms in inflammatory conditions leading to endothelial 
barrier disruption (Figure 3). (I) The cytoskeletal proteins reorganization: the 
remodeling of cortical actin of resting EC into cell-spanning cytosolic stress fibers. (II) 
The activation of the contractile machinery by phosphorylation of myosin light chain2 
(ppMLC2 T18/S19). 16,17 (III) The disassembly of  adhesion junctions induced by tyrosin 
phosphorylation of the adhesion protein vascular endothelial cadherin (pVECY731). 
This leads to a dissociation of intracellular regulatory proteins (β-catenin, p120ctn) 
from VEC, which results in its internalization or degradation.18 All these factors 
together lead to the formation of interendothelial gaps, which disturb the endothelial 
barrier function (image in Figure 3). 
Under inflammatory conditions, permeability-inducing factors such as histamine, 
TNFα, or thrombin are generated and released from platelets, mast cells, monocytes/ 
macrophages, and vascular cells. 19, 16 They activate specific receptors and increase 
the intracellular Ca2+ concentration ([Ca2+]i) (Figure 4). The [Ca2+]i-increase leads to 
activation of Ca2+/calmodulin-dependent myosin light chain (MLC) kinase (MLCK), 
which phosphorylates MLC2 and therefore promotes the interaction of myosin2 with 
actin filaments, leading to cellular contraction. Activation of the small monomeric 
GTPase RhoA with its effector Rho kinase (ROCK) also contributes to MLC2 
phosphorylation in endothelial cells by inhibition of myosin light chain phosphatase 
(MLCP). RhoA (via ROCK) is also known to be a central regulator of the actin 
cytoskeleton in terms of stress fibers formation, and thus is involved in the 
mechanism of cell retraction.  
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Additionally, RhoA as well as the activation of Ca2+-dependent protein kinase C 
(PKC) isoform PKC-α, increases induction of endothelial permeability by disrupting 
the vascular endothelial cadherin (VEC) junctional complex. Therefore, the 
inflammation-induced Ca2+-signaling affects all three key parameters of endothelial 
permeability.  
 
 
 
Figure 3: Structure of the key parameters of endothelial permeability. Adhesive junctions formed by 
VEC (1) and its regulatory proteins, the catenins (3), interconnect endothelial cells stabilizing 
the endothelial barrier. Contractile forces occure along the stress-fibers (2), via interaction 
with myosin (4). The loss of VEC connections between the cells and the induction of 
contractile forces lead to an opening of endothelial gaps (white arrows). The microscopic 
image shows a thrombin activated endothelial monolayer with the typical fringy, 
uncontinuous VEC seam (green) and stress-fibers (red).  
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Figure 4: Inflammation-induced endothelial activation by mediators like TNFα, thrombin, or histamine, 
results in an increase of [Ca2+]i levels. The subsequently induced downstream signaling of 
MLCK, RhoA and PKC affects the key parameters of endothelial permeability, which results 
in an increased in EHP. 
 
2.2.2 Thrombin induced Ca2+ increase   
 
Thrombin, a procoagulant serin protease, showed up to be the model substance for 
inflammation-induced endothelial permeability in vitro,20-22 mediating its acute effects 
be raising intracellular Ca2+.4, 19, 23 An [Ca2+]i-response to thrombin is characterized 
by two distinct phases, including a transient rise corresponding to the release of Ca2+ 
from intracellular stores, and a more sustained increase due to an entry of Ca2+ 
across the plasmalemma.23 Each phase can regulate discrete cellular functions. As 
an example, activation of endothelial cell phospholipase A2 depends on Ca2+ 
release, whereas inhibition of the adenylyl cyclase (AC) requires Ca2+ entry. 24-26 
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[Ca2+]i is induced by activation of the G protein-coupled protease-activated receptor-1 
(PAR-1) (Figure 5). The Gαq protein activates phospholipase C (PLC), which 
catalyzes production of inositol triphosphat (IP3) and diacylglycerol (DAG) from 
phosphatidylinositol 4,5-bisphosphate (PIP2).4 IP3 in turn activates the IP3 receptor in 
the endoplasmatic reticulum (ER) to cause the rapid release of sequestered Ca2+ into 
the cytosol, which forms the fast and strong first Ca2+increase (first phase of the 
intracellular Ca2+ signal). This Ca2+increase by ER-depletion activates the store-
operated Ca2+ channels (SOCs) at the cell membrane, which elicits Ca2+ entry from 
the extracellular milieu leading to reduced, but sustained Ca2+-influx (second phase 
of the intracellular Ca2+-increase). Beside SOC, receptor-operated Ca2+ channels 
(ROCs) are activated by DAG induction. ROCs lead to a Ca2+-influx from the 
extracellular space, and intensifies the Ca2+ increase in the first phase of  Ca2+ 
signaling.19  
 
 
Figure 5: Pathway of thrombin-induced [Ca2+]i increase. 
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3  Endothelial barrier protective cAMP- signaling 
 
Cyclic adenosine 3´,5´-monophosphate (cAMP) is an universal second messenger, 
which is produced from ATP by adenylyl cyclase (AC) upon activation of Gs protein-
coupled receptor (GPCR) and degraded to 5`AMP by phosphodiesterases (PDE) 
(Figure 6). In the vascular system, cAMP influences contraction and relaxation of 
vascular smooth muscle cells as well as their movement, and the permeability of 
vascular endothelial cells.27 Elevation of cAMP in endothelial cells has been 
recognized to increase barrier function. cAMP-elevating drugs are known to reduce 
inflammation-induced permeability and edema formation.28-31 A few years ago this 
inhibition was thought to be mediated by an activation of protein kinase A (PKA) and 
its effector vasodilator-stimulated phosphoprotein (VASP).32 Recent work suggests 
that cAMP directly activates a new family named exchange proteins directly activated 
by cAMP (Epac), which seems to be the major regulator of endothelial barrier 
function. 33-35,36 They are guanine nucleotide exchange factors (GEFs) and activate 
Rap1, a small GTPases of the Ras family. This pathway represent a PKA 
independent and novel mechanism for governing signaling specificity within the 
cAMP cascade.37, 38  
cAMP stabilizes the endothelial barrier by targeting all three key parameters of  
endothelial permeability. cAMP abrogates the RhoA-induced inhibition of MLCP and 
in consequence induces contractile forces that lead to cell rounding. The cAMP-
dependent formation of cortical actin relies on an activation of cortactin and stabilizes 
the endothelial barrier function. The blocking of RhoA activity as well as the activation 
of cortactin is caused by cAMP-induced activation of Rac1. The increase of  [cAMP]i-
levels also results in a stabilization of AJ by activating cortactin and stabilizing VEC-
catenin binding via Rap1.39, 40, 41 
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Figure 6: cAMP-dependent endothelial barrier protection due to targeting of the key parameters of 
endothelial permeability. 
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4 Hawthorn extract WS® 1442  
 
Hawthorn extract is worldwide used as herbal remedy for the treatment of CVD, and 
especially in heart failure. WS® 1442 is the most used extract of the leaves and the 
flowers of Crataegus monogyna and laevigata (Figure 7). In contrast to several other 
Crataegus products, which are mostly available as nutraceuticals, it is registered as a 
phytopharmaceutical medicinal product for the treatment of early stages of 
congestive heart failure corresponding to stage II of the New York Heart Association 
(NYHA) classification. WS® 1442 is a dry extract from Crataegus leaves with flowers 
(4-6.6:1), extract solvent ethanol 45% (w/w), adjusted to a content of 17.3-20.1% of 
oligomeric procyanidines (OPC) (Figure 8). Besides OPC, WS® 1442 contains mainly 
flavonoids (flavones, flavonols), including hyperoside, rutin, and vitexin (Figure 9) as 
well as triterpenoids and phenol carboxylic acids. This standardized quality and 
different composition compared to other products is the requirement for the save and 
successful use, as a natural compound in drug therapy, or for scientific purposes. 
 
 
 
Figure 7: leaves and flowers of Hawthorn 
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5 
Figure 8: Structures of proanthocyanidines: (1) catechin, (2) Epicatechin, (3) procianidine B2, (4) 
procianidine B4, (5) procianidine B5. 
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Figure 9:  
R1 R2 R3 R4 R5  
H OH β-D-Glu H OH vitexin 
O-β-D-Gal OH H OH OH hyperoside 
O-β-D-Glu-(61)-α-L-
Rha 
OH H OH OH rutin 
 
4.1 Pharmacology and clinical efficancy of WS® 1442 
 
The hawthorn-extract WS® 1442 consists of a complex mixture of active constitutes, 
and affects a multitude of pharmacological targets. A positive inotropic effect is 
possibly mediated by a cAMP-independent inhibition of Na+/K+-ATPase. A 
concentration-dependent increase of myocardial contractility, accompanied by a 
transient raise in [Ca2+]i, was observed in in vitro experiments with human cardiac 
tissue.42-44 In contrast to cardiac glycosides, WS® 1442 possesses pronounced anti-
arrhythmic properties, by both prolonging the action potential and the refractory 
period.45 Furthermore, a vasorelaxation by an endothelium-dependent NO-mediated 
mechanism was described recently.46 In animal models of ischaemia and 
reperfusion, a significant reduction of ventricular fibrillation, tachycardia, area of 
infarction, and rate of mortality has been observed. An increased coronary blood flow 
as well as reduced endothelial dysfunction and inhibition of lipid oxidation properties 
may contribute to these cardio protective effects of WS® 1442.47, 48  
In clinical trials, WS® 1442 showed an improvement of the exercise capacity, an 
increased ejection fraction, and decreased heart failure symptoms.49, 50 The safety 
and efficiency of this herbal extract in congestive heart failure (CHF) during short and 
long term administration was also confirmed.51 In 2008, Holubarsch et al. published 
the SPICE-trial (Survival and Prognosis: Investigation of Crataegus Extract WS®1442 
in CHF)52. This randomized, double-blind, placebo-controlled multicenter study 
included adults suffering from CHF (NYHA class II or III) and reduced left ventricular 
ejection fraction, which received 900 mg/day WS® 1442 or placebo for 24 months as 
an add-on therapy. Primary endpoint was the period until the first cardiac event 
occurred. WS® 1442 as a positive inotropic active drug, showed no increase in 
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mortality,53 and therefore confirmed its safety and standing as a valuable drug for 
symptoms control in CHF. 
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5 Aim of the Study 
 
Inflammation-activated endothelial cells (EC) lose their barrier function leading to 
hyperpermeability19. As a result of the loss of barrier integrity, edema formation 
occurs and contributes to the pathogenesis of several disorders, including sepsis, 
heart failure, atherosclerosis, and asthma. 54-57, 12 These diseases represent some of 
the most important death-inducing factors, and endothelial hyperpermeability (EHP) 
poses a very important, highly intriguing central process of all these disorders. 
However, a specific pharmacological drug targeting remains widely lacking, and 
therefore no reliable standard therapy for inflammation induced vascular leakage is 
available. If one considers that EP is a hallmark of inflammation, which is involved in 
the progression of so many diseases, the search for a permeability-inhibiting 
compound seems to be an important today’s unsolved task in modern medicine. 
WS® 1442 is an approved drug for the treatment of congestive heart failure according 
to the New York Heart Association (NYHA) functional class II. The pharmacological 
properties of WS® 1442 have been predominantly investigated with regard to the 
direct effects on the heart: positive inotropic effects, anti-arrhythmic properties and 
enhanced coronary blood flow44, 47, 58. Although congestive heart failure is 
accompanied with edema formation59, studies investigating potential beneficial 
effects of administered WS® 1442 on endothelial barrier dysfunction in vitro or in vivo 
are lacking.  
Thus, we focused on the extra-cardiac actions of WS® 1442 extract concerning 
endothelial barrier protection in inflammatory conditions. The aims of our study were: 
 
(I)  to clarify the general potential of WS® 1442 to inhibit inflammatory endothelial 
activation, and to protecting against inflammation-induced endothelial hyper-
permeability in vitro and in vivo, 
 
(III) to decipher the mechanisms by which WS® 1442  influences the key regulators 
of  endothelial permeability activation, and  
 
(IV) to relate functions to classes of chemical compounds of the extract. 
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II  MATERIALS AND METHODS 
1   Materials 
1.1 Crataegus extract WS® 1442 
 
WS® 1442 is a well-defined extract of the leaves and the flowers of Crataegus 
monogyna and laevigata and was kindly provided by Dr. Willmar Schwabe GmbH & 
Co.KG (Karlsruhe, Germany). 
 
For experiments, WS® 1442 was freshly dissolved in growth medium at a maximal 
concentration of 10,000 µg/ml. Tanning agents were separated by column 
chromatography with Sephadex LH20 and 75% EtOH (Separation was kindly 
performed by Dr. Guido Jürgenliemk Pharmaceutical Biology, University of 
Regensburg, Germany) and the tanning agent free extract was used for in vivo and in 
vitro experiments. 
 
WS® 1442 fractions were used in the concentrations comparable to 100 µg/ml of the 
complete extract (separated by column chromatography with Sephadex LH20. 
Separation was kindly performed by Dr. Willmar Schwabe Pharmaceuticals). 
 
WS® 1442 
fraction # 
eluate mass [%] of 
complete extract 
main compounds 
30 H2O 56.83 non-phenolic, aliphatic 
compounds 
32 EtOH 95% / H2O 17.00 flavanoids 
34 MeOH 12.17 oligomeric proanthocyanidines 
36 acetoniltrile 70% 
/ H2O 
 8.13 proanthocyanidines n>4 
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1.2 Biochemicals, Inhibitors and Dyes  
 
8-Bromo-cAMP     Biotrend, Cologne, Germany  
8-pCPT-2´-O-Me-cAMP    BIOLOG, Bremen, Germany 
β-glycerophosphat     Calbiochem, Darmstadt, Germany 
BSA (gamma globulin free)   Sigma Aldrich, Taufkirchen, Germany 
cAMPS-Rp      Biotrend, Cologne, Germany   
CompleteTM       Roche, Mannheim, Germany 
FluorSave aqueous mounting medium   VWR, Darmstadt, Germany 
FITC-Dextran 40 kDa    Sigma Aldrich, Taufkirchen, Germany 
forskolin      Biotrend, Cologne, Germany  
FURA-2, AM Ester     Biotrend, Cologne, Germany   
histamine      Sigma Aldrich, Taufkirchen, Germany 
L-NAME Cayman Chemical Company, 
Michigan, USA 
MTT       Sigma Aldrich, Taufkirchen, Germany 
NaF        Merck, Darmstadt, Germany 
Na3VO4       ICN Biomedicals, Aurora, Ohio, USA 
PageRulerTM      Fermentas, St. Leon-Rot, Germany 
PMSF       Sigma Aldrich, Taufkirchen, Germany 
thapsigargin      Sigma Aldrich, Taufkirchen, Germany 
thrombin (human)     Sigma Aldrich, Taufkirchen, Germany 
TNFα       Sigma Aldrich, Taufkirchen, Germany 
Triton X-100      Sigma Aldrich, Taufkirchen, Germany 
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1.3 Technical equipment 
 
Vi-CELL™ (Beckman Coulter)    Cell viability analyser 
FACSCalibur (Becton Dickinson)   Flow cytometer 
Axiovert 25 (Zeiss)      Inverted microscope 
Axiovert 200 (Zeiss)     Inverted microscope 
LSM 510 Meta (Zeiss)    Confocal laser scanning microscope 
Sunrise™ (Tecan)  Plate-reading multifunction 
photometer 
Curix 60 (Agfa)      Tabletop film processor 
Thermoshake THO 500 (Gerhardt)   Incubator shaker 
Nucleofector™ II (Amaxa)    Electroporation device 
Cyclone Storage Phosphor System  Phosphorimager 
 
2   Cell Culture 
 
2.1 Solutions and reagents 
 
The following solutions and reagents were used for the isolation as well as for the 
cultivation of endothelial cells. 
 
PBS (pH 7.4) 
NaCl    123.2  mM 
Na2HPO4   10.4  mM 
KH2PO4   3.2  mM 
H2O 
 
PBS+ Ca2+/Mg2+ (pH 7.4) 
NaCl    137  mM 
KCl    2.68  mM 
Na2HPO4   8.10  mM 
KH2PO4   1.47  mM 
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MgCl2   0.25  mM 
CaCl2   0.5  mM 
H2O 
 
Trypsin/EDTA (T/E) 
Trypsin   0.05  % 
EDTA   0.20  % 
PBS 
 
Growth medium 
ECGM   500  ml 
Supplement   23.5  ml 
FCS    50  ml 
Antibiotics   3.5  ml 
 
Collagen A  
Collagen A   10  % 
PBS  
 
Freezing medium 
FCS    50  % 
DMSO   8  % 
ECGM 
 
Stopping medium 
M 199   500  ml 
FCS    50  ml 
 
Collagen G 
Collagen G   0.001  % 
PBS 
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Cell culture reagents 
Collagen A       BIOCHROM AG, Berlin, Germany 
Collagen G       BIOCHROM AG, Berlin, Germany 
Collagenase A      Roche, Mannheim, Germany 
Culture flasks, plates, dishes    TPP, Trasadingen, Switzerland 
ECGM containing supplement and antibiotics  Provitro, Berlin, Germany 
FCS       PAA, Pasching, Austria 
ibidi slides       ibidi GmbH, Munich, Germany 
M199        PAN Biotech, Aidenbach, Germany 
 
For heat inactivation, FCS was partially thawed for 30 min at room temperature. 
Subsequently, it was totally thawed at 37°C using a water bath. Finally, FCS was 
inactivated at 56°C for 30 min. Thereafter, 50 ml aliquots of heat inactivated FCS 
were stored at -20°C. 
 
2.2 HMEC-1 – human microvascular endothelial cells 
 
The cell line CDC/EU.HMEC-1 was kindly provided by the Centers for Disease 
Control and Prevention (Atlanta, GA, USA). The immortalized HMEC-1 cell line was 
created by transfection of human dermal microvascular endothelial cells with a 
plasmid coding for the transforming SV40 large T-antigen. HMEC-1 were shown to 
retain endothelial morphologic, phenotypic, and functional characteristics.60, 61 
 
2.3 HUVEC – human umbilical vein endothelial cells 
 
Human umbilical cords were kindly provided by hospitals from the Munich area. After 
childbirth, umbilical cords were stored in PBS+Ca2+/Mg2+ containing Penicillin (100 
U/ml) and Streptomycin (100 µg/ml), 4°C. Cells were isolated within one week. The 
umbilical vein was washed with PBS+Ca2+/Mg2+, filled with 0.1 g/l collagenase A, and 
incubated for 45 min at 37°C. To isolate endothelial cells, the vein was flushed with 
stopping medium and the eluate was centrifuged (1000 rpm; 5 min). Afterwards, cells 
were replaced in growth medium and plated in a 25 cm2 flask. After reaching 
confluency, cells were trypsinized and plated in a 75 cm2 flask. Experiments were 
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performed using cells at passage 3, when they were at least two days in a confluent 
state. 
 
2.4 Passaging 
 
After reaching confluency, cells were either sub-cultured 1:3 in 75 cm2 culture flasks 
or seeded either in multiwall plates or dishes for experiments. For passaging, 
medium was removed and cells were washed twice with PBS before incubation with 
trypsin/ethylene diamine tetraacetic acid (EDTA) (T/E) for 1-2 min at 37°C. 
Thereafter, cells were gradually detached and the digestion was stopped using 
stopping medium. After centrifugation (1,000 rpm, 5 min, 20°C), the pellet was 
resuspended in growth medium and cells were plated. 
 
2.5 Long-time storage 
 
For freezing, confluent HMECs from a 75 cm² flask were trypsinized, centrifuged 
(1,000 rpm, 5 min, 20°C), and resuspended in 3 ml ice-cold freezing medium. 1.5 ml 
aliquots were frozen in cryovials. After storage at -80°C for 24 h, aliquots were 
moved to liquid nitrogen for long-time storage. 
For thawing, a cryovial was warmed to 37°C and the content was immediately 
dissolved in prewarmed growth medium. In order to remove DMSO, cells were 
centrifuged, resuspended in growth medium, and transferred to a 75 cm² culture 
flask. 
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3   Protein sample preparation 
 
3.1 Total cell lysate 
 
Endothelial cells were treated as indicated, washed once with ice-cold PBS and 
subsequently lysed in Ripa lysis buffer. Immediately, cells were frozen at -85°C. 
Afterwards, cells were scraped off and transferred to Eppendorf tubes (Peske, 
Aindling-Arnhofen, Germany) before centrifugation (14,000 rpm, 10 min, 4°C). 
Protein concentration was determined using the BCA or the Bradford assay.  
Laemmli sample buffer (3x) was added and samples were heated at 95°C for 5 min. 
The reducing agent β-mercaptoethanol cleaves disulfide bonds and boiling leads to 
complete denaturation of the proteins. SDS is an anionic detergent that attaches to 
hydrophobic parts of the proteins, resulting in permanent negatively charged 
proteins. Samples were kept at -20°C until Western blot analysis. 
For the protection of phosphorylated proteins the cells were washed with modified 
PBS containing activated Na2VO3 and H2O2 (s. modified cell washing solution), and 
the Ripa lysis buffer additionally contained H2O2, β-glycerophosphate and 
pyrophosphate (s. modified Ripa lysis buffer). 
 
Modified cell washing 
solution 
activated Na2VO4  600 µM 
H2O2   600 µM 
PBS 
 
Modified Ripa lysis buffer 
NaCl      150  mM 
Tris      50  mM 
Nonidet P-40    1  % 
Deoxycholate    0.25  % 
SDS      0.10  % 
β-glycerophosphate  3 mM 
pyrophosphate   10 mM 
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H2O 
add before use: 
CompleteTM   4  mM 
PMSF   1  mM 
NaF    1  mM 
activated Na2VO3  1  mM 
H2O2   600 µM 
 
Laemmli sample buffer (3x) 
Tris-HCl   187.5  mM 
SDS    6  % 
Glycerol   30  % 
Bromphenolblue  0.025  % 
H2O 
add before use: 
β-mercaptoethanol  12.5  % 
 
3.2 Membrane fractionation 
 
HUVEC lysates were separated into a soluble (cytosolic) and a particulate 
(membranous) fraction, as described previously by Li H et al.62 HUVECs were treated 
as indicated, washed twice with ice-cold PBS, and homogenized in lysis buffer. 
Lysates were centrifuged at 100,000 g for 1 hour. The supernatant (cytosolic fraction) 
was collected, the pellet was washed in lysis buffer containing 1.0 M NaCl, and 
centrifuged at 100,000 g for 30 minutes. The supernatant was discarded and the 
pellet was solubilized with lysis buffer containing 20 mM CHAPS at 4°C for 30 
minutes. After centrifugation at 100,000 g for 1 hour, the supernatant was kept as 
membranous fraction. Both fractions were used for Western blotting. 
 
Membrane lysing buffer   
Tris-HCl  pH 7.5 0.05  M 
EDTA   0.5 mM 
EGTA   0.5 mM 
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Glutathione  7.0 mM 
Glycerol  10 % 
H2O 
add before use: 
PMSF     1.0  mM  
Complete®        4  mM 
 
3.3 Extraction of nuclear protein 
 
HUVEC were grown in 6-well plates until reaching confluency and were treated as 
indicated in the respective figures. Nuclear extracts were prepared according to the 
method of Schreiber et al.63 as follows: after treatment, cells were washed twice with 
ice-cold PBS, scraped off in PBS with a rubber cell scraper, centrifuged, and 
resuspended in an ice-cold cytosol lysing buffer. Cells were incubated on ice for 15 
min. Nonidet P-40 was added to the cells and after vigorous vortexing the 
homogenate was centrifuged. The nuclear pellet was resuspended by vigorous 
rocking for 15 min at 4°C in nucleus lysing buffer containing HEPES pH 7.9 20 mM, 
NaCl 400 mM, EDTA 1 mM, EGTA 0.5 mM, glycerol 25 %, DTT 1 mM, PMSF 1 mM, 
and Complete® 2 %. The nuclear extract was centrifuged and the supernatant 
containing nuclear proteins was frozen at -80°C. The protein concentrations were 
determined by the method of Bradford.64  
 
Cytosol lysing buffer   
HEPES  pH 7.9 10  mM 
KCL   10 mM 
EDTA   0.1 mM 
EGTA   0.1 mM 
DTT   1 mM 
H2O 
add before use: 
PMSF     0.5  mM  
Complete®        1  % 
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Nucleus lysing buffer   
HEPES  pH 7.9 20  mM 
NaCl   400 mM 
EDTA   1 mM 
EGTA   0.5 mM 
Glycerol  25 % 
DTT   1 mM 
 H2O 
add before use: 
PMSF     1  mM  
Complete®        2  % 
 
4   Protein Quantification  
 
4.1 Bicinchoninic protein assay (BCA) 
 
Bicinchoninic (BCA) Protein Assay (BC Assay reagents, Interdim, Montlucon, 
France) was performed as described previously.65 10 µl protein samples were 
incubated with 200 µl BC Assay reagent for 30 min at 37°C. Absorbance of the blue 
complex was measured photometrically at 550 nm (Tecan Sunrise Absorbance 
reader, TECAN, Crailsheim, Germany). Protein standards were obtained by diluting a 
stock solution of Bovine Serum Albumin (BSA, 2 mg/ml). Linear regression was used 
to determine the actual protein concentration of each sample. 
 
4.2 Bradford assay 
 
Bradford Assay (Bradford solution, Bio-Rad, Munich, Germany) was performed as 
described previously.64 It employes Coomassie Brillant Blue as a dye, which binds to 
proteins. 10 µl protein samples were incubated with 190 µl Bradford solution (1:5 
dilution in water) for 5 min. Thereafter, absorbance was measured photometrically at 
592 nm (Tecan Sunrise Absorbance reader, TECAN, Crailsheim, Germany). Protein 
standards were achieved as described above (BCA Assay). 
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5  Western blot transfer 
 
In order to employ equal amounts of proteins in all samples for Western blot analysis, 
protein concentrations were determined using the Bicinchoninic Protein Assay (BCA). 
After measurement, protein concentration was adjusted by adding Laemmli sample 
buffer (1x).  
 
5.1 SDS-PAGE 
 
Proteins were separated by discontinuous SDS-polyacrylamid gel electrophoresis 
(SDS-PAGE) according to Laemmli.66 Equal amounts of protein were loaded on gels 
and separated using the Mini-PROTEAN 3 electrophoresis module (Bio-Rad, Munich, 
Germany). Discontinuous polyacrylamide gels were used consisting of  a separation 
and stacking gel. The concentration of RotiphoreseTM Gel 30 (acrylamide) in the 
separating gel was adjusted for an optimal separation of the proteins depending on 
their molecular weights (Table 1). Electrophoresis was carried out at 100 V for 21 
min for protein stacking and 200 V for 45 min for protein separation. The molecular 
weight of proteins was determined by comparison with the prestained protein ladder 
PageRulerTM. 
 
Table 1: Acrylamide concentration in the separation gel: 
 
Protein        acrylamide concentration  
phos. MLC, pp38, RhoA, Rac1, Rap1, βActin, phos. VASP   15  % 
VEC, phos. VEC, p120ctn, β-catenin, phos. PKC(pan),  
phos. PKC-Sub., cortactin, phos cortactin,       10  % 
 
 
 
Separation gel 10/15 % 
RotiphoreseTM Gel 30  33.3/50 % 
Tris (pH 8.8)   375  mM  
SDS     0.1  % 
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TEMED    0.1  % 
APS     0.05  % 
H2O 
Stacking gel 
RotiphoreseTM Gel 30  40  % 
Tris (pH 6.8)   125  mM 
SDS     0.1  % 
TEMED    0.2  % 
APS     0.1  % 
H2O 
 
Electrophoresis buffer 
Tris     4.9  mM 
Glycine    38  mM 
SDS     0.1  % 
H2O 
 
5.2 Tank-electroblotting 
 
After protein separation, proteins were transferred onto a nitrocellulose membrane 
(Hybond-ECLTM, Amersham Bioscience, Freiburg, Germany) by electro tank blotting. 
Electroblotting, also denoted as Western blotting, is the most commonly used method 
to transfer proteins from a gel to a membrane.67 A blotting sandwich was prepared in 
a box filled with 1x Tank Buffer to avoid bubbles as follows: cathode – pad – blotting 
paper – separating gel (from SDS-PAGE) – nitrocellulose membrane – blotting paper 
– pad – anode. Pads, papers, and membrane were equilibrated with 1x Tank buffer 
15 minutes prior to running the tank blot. Sandwiches were mounted in the Mini 
Trans-Blot® system (Bio-Rad, Munich, Germany), ice-cold 1x Tank buffer filled the 
chamber and a cooling pack was inserted to avoid excessive heat. Transfers were 
carried out at 4°C, either at 100 V for 90 minutes or at 24 V overnight (especially for 
high-molecular weight proteins).   
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5x Tank buffer   
Tris base   15.2  g 
Glycine    72.9  g 
H2O                ad 1.0 l 
 1x Tank buffer   
5x Tank buffer  200  ml 
Methanol    200  ml 
H2O                ad 1.0 l 
 
5.3 Protein detection 
 
Prior to the immunological detection of the relevant proteins, unspecific protein 
binding sites were blocked. Therefore, the membrane was incubated in Blotto 5% or 
BSA 5% for 2 h at room temperature. Afterwards, detection of the proteins was 
performed by incubating the membrane with the respective primary antibody at 4°C 
overnight. After three washing steps with PBS containing 0.1% Tween (PBS-T), the 
membrane was incubated with the secondary antibody, followed by 3 additional 
washing steps. All steps regarding the incubation of the membrane were performed 
under gentle agitation. In order to visualize the proteins, two different methods have 
been used depending on the labels of secondary antibodies. 
 
5.4 Enhanced chemiluminescence 
 
Membranes were incubated for 2 h with HRP-conjugated secondary antibodies. For 
detection, luminol was used as a substrate. The membrane was incubated with  ECL 
(enhanced chemoluminescence) solution for 1 minute (ECL Plus Western Blotting 
Detection Reagent RPN 2132, GE Healthcare, Munich, Germany). The appearing 
luminescence was detected by exposure of the membrane to an X-ray film (Super 
RX, Fuji, Düsseldorf, Germany) and subsequently developed with a Curix 60 
Developing system (Agfa-Gevaert AG, Cologne, Germany).  
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5.5 Infrared Imaging 
 
Secondary antibodies coupled to IRDyeTM 800 and Alexa Fluor® 680 with emission at 
800 and 700 nm, respectively, were used (Table 3). Membranes were incubated for 
1 h. Protein bands of interest were detected using the Odyssey imaging system (Li-
Cor Biosciences, Lincoln, NE). After scanning the membrane with two-color 
detection, bands could be quantified using the Odyssey software. Primary antibodies 
used for protein detection are listed in Table 2.  
 
Table 2: Primary antibodies 
 
Antigen  Source  Dilution  in   Provider 
actin    mouse monoclonal 1:10,000 Blotto 1 % Chemicon 
β-catenin   rabbit polyclonal 1:10,000 Blotto 1 % Santa Cruz 
VEC    mouse monoclonal 1:10,000 Blotto 1 % Santa Cruz  
phos.VEC Y731  rabbit polyclonal 1:5,000 Blotto 1 % Biosource 
p120ctn   rabbit polyclonal 1:10,000 Blotto 1 % Santa Cruz 
phos. cortactinY421  rabbit polyclonal 1:1,000 BSA  5 % Cell Signaling 
phos. MLC T18/S19  rabbit polyclonal 1:1,000 BSA  1 % Biosource 
phos. PKA-sub.  rabbit monoclonal 1:1,000 Blotto 5 % Cell Signaling 
phos. PKC-sub.  rabbit polyclonal 1:1,000 BSA  5 % Cell Signaling 
phos. PKC(pan)T514  rabbit polyclonal 1:1,000 BSA  5 % Cell Signaling 
phos. p38T180/Y182  mouse monoclonal 1:5,000 Blotto 5 % Cell Signaling 
phos.VASPS157  rabbit polyclonal 1:1,000 BSA  1 % Cell Signaling 
Rac1    mouse monoclonal 1:1,000 Blotto  3 % UPSTATE 
Rap1    rabbit polyclonal 1:1,000 BSA  3 % PIERCE 
RhoA    mous monoclonal 1:500  BSA  3 % PIRECE  
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Table 3: Secondary antibodies 
 
Antibody     Dilution  in   Provider 
Goat anti-mouse IgG1: HRP   1:1,000  Blotto 1%  Biozol 
Goat anti mouse IgG2b: HRP  1:1,000 Blotto 1% Southern Biotech. 
Goat anti-rabbit: HRP    1:1,000  Blotto 1%  Dianova 
Alexa Fluor® 680 goat anti-mouse IgG  1:10,000  Blotto 1%  Molecular Probes 
Alexa Fluor® 680 goat anti-rabbit IgG  1:10,000  Blotto 1%  Molecular Probes 
IRDyeTM 800 goat anti-rabbit IgG  1:10,000  Blotto 1%  Rockland 
 
5.6  Stripping and reprobing 
 
In order to remove primary and secondary antibodies from the membrane 
(“stripping”), blots were incubated twice in stripping buffer for 15 min at room 
temperature. After extensive washing, stripping efficiency was confirmed by 
scanning/detecting the membrane to see if signals have been removed. 
Subsequently, the blot was re-blocked with Blotto 5% for 2 h and incubated with 
antibodies. 
 
Stripping buffer (pH 2.0) 
Glycine    25  mM 
SDS     0.1  % 
H2O 
 
6   Electrophoretic mobility shift assay (EMSA) 
 
6.1 Radioactive labeling of consensus oligonucleotides 
 
Double-stranded oligonucleotide probes containing the consensus sequence either 
for AP-1 (5’-CGCTTGATGAGTCAGCCGGAA-3’) or for NF-κB (5’-AGTTGAGGG 
GACTTTCCCAGGC-3’) (both from Promega, Mannheim, Germany) were 5’-end-
labeled with adenosine 5’-[γ-32P] triphosphate (3,000 Ci/mmol) (Amersham, Freiburg, 
Germany) by using the T4 polynucleotide kinase (PNK) (USB, Cleveland, USA), 
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which catalyzes the transfer of the terminal phosphate of ATP to the 5’-hydroxyl-
termini of DNA. The oligonucleotides were incubated with T4 PNK for 10 min at 37°C 
and the reaction was stopped by adding EDTA solution (0.5 M). The radiolabeled 
DNA was separated from unlabeled remnants by using NucTrap probe purification 
columns (Stratagene, La Jolla, USA). Radiolabeled DNA was eluated from the 
column by STE buffer pH 7.5 and frozen at -20°C. 
 
STE buffer pH 7.5  
Tris-HCl   10  mM 
NaCl    100 mM 
EDTA    1 mM 
H2O 
 
6.2 Binding reaction and electrophoretic separation 
 
Equal amounts of nuclear protein (approx. 2 µg) were incubated for 5 min at room 
temperature in a total volume of 14 µl containing poly(dIdC) 2 µg and reaction buffer 
3 µl. Subsequently, 1 µl of the radiolabeled oligonucleotide probe (approx. 300,000 
cpm) was added. After incubation for 30 min at room temperature, the nucleoprotein-
oligonucleotide complexes were resolved by electrophoresis (Mini-Protean 3, Bio-
Rad, Munich, Germany) on non-denaturating polyacrylamide gels (4.5 %). TBE was 
used as electrophoresis buffer. Bands were visualized by applying the gels to 
Cyclone Storage Phosphor Screens (Canberra-Packard, Dreieich, Germany) and 
analysis by a phosphorimager (Cyclone Storage Phosphor System, Canberra-
Packard, Dreieich, Germany).  
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Non-denaturating  
polyacrylamide gels 4.5%  
10x TBE    5.3  % 
RotiphoreseTM Gel 30  15.8  % 
Glycerol                   2.6 % 
TEMED   0.05 % 
APS    0.08 % 
H2O 
 
10x TBE pH 8.3 
Tris    0.89 M 
Boric acid   0.89 M 
EDTA    0.02 M 
H2O 
5x Binding buffer pH 7.5  
Glycerol   20  % 
MgCl2    5  mM 
EDTA                    2.5 mM 
NaCl    250 mM 
Tris-HCl    50 mM 
H2O 
 
Gel loading buffer pH 7.5  
Tris-HCl    250 mM 
Bromphenol blue            0.2 % 
Glycerol   40 % 
H2O 
 
 Reaktion buffer 
DTT    2.6 mM 
5x binding buffer            90 % 
gel loading buffer  10 % 
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7   Transfection of cells 
 
HUVECs were transiently transfected with plasmids for pEGFP-C1-actin, which was 
kindly provided by S. Linder (Inst f. Prophylaxe und Epidemiologie der 
Kreislauferkrankungen). For electroporation the Nucleofector® II device in 
combination with the HUVEC Nucleofector® Kit (both from Amaxa, Cologne, 
Germany) was used. Plasmids were amplified in the E. coli strain DH5α and 
purificated by using the EndoFree Plasmid Maxi Kit (Qiagen GmbH, Hilden, 
Germany). Expression procedures were done according to the provided protocol. For 
each transfection, 1x106 HUVECs were suspended in 100 µl HUVEC Nucleofector 
Solution including 5 µg of the respective plasmid. Electroporation was performed 
according to Amaxa protocols (program A-034). After transfection, cells were seeded 
into ibidi µ-slides (8-well ibiTreat, ibidi GmbH, Munich, Germany, 300,000 cells per 
well). Experiments were performed 48 h after transfection. 
 
8   Rac, Rho and Rap pull-down assay 
 
In a pull-down assay, the activation state of GTPases can be analyzed. The assay is 
based on the principle that only the active form of the GTPase interacts with its 
specific downstream effectors. The GTPase-binding domains from these downstream 
effectors are expressed as recombinant glutathione S-transferase (GST) fusion 
proteins immobilized on glutathione resin and can be used for affinity precipitation 
(pull-down) of the active GTPase from cell lysates. Pulled-down active GTPases are 
eluted from the resin and detected by immunoblotting with a specific antibody. 
 
Pull-down assays were performed using the RhoA Activation Assay Kit 89854, Rap1 
Activation Assay Kit 89872 (both from PIERCE, Rockford, IL, USA) and Rac1/Cdc42 
Activation Assay Kit 17-441 (from Millipore, Billerica, MA, USA). HUVECs were 
seeded into 100 mm2 dishes and grown 3 days (long confluence). Procedures were 
done according to the provided protocol. For adjustment of protein contents of the 
respective samples, protein concentration was determined using the Bradford-assay. 
Proteins were detected by Western Blot analysis. 
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9   Macromolecular permeability assay 
 
HMECs (0.125 x 106 cells/well) were seeded on collagen G-coated 12-well 
Transwell® plate inserts (pore size 0.4 µm, polyester membrane; Corning, New York, 
USA) and cultured for 48 h. FITC-dextran (40 kDa; 1 mg/ml; Sigma-Aldrich) was 
given to the upper compartment at t = 0 min. Cells were treated as indicated. 
Samples were taken from the lower compartment at t = 0/5/10/15/30 min. The 
fluorescence increase (ex 485/em 535) of the samples was detected with a 
fluorescence plate reader (SpectraFluor Plus, Tecan Deutschland GmbH). The mean 
fluorescence of untreated cells at t = 30 was set as 100%. The data are expressed 
as the percent increase of fluorescence versus the control. 
 
                              
 
 
Figure 10: Close up of a Transwell® insert with a HMEC monolayer 
 
10 Ca2+-measurement 
 
Changes in intracellular calcium levels can be analyzed by ion sensitive indicators, 
whose light emission reflects the local concentration of the ion. Fura-2 is a calcium 
indicator often used in the esterified form Fura-2 acetoxymethyl ester (Fura-2-AM). 
The acetoxymethyl ester group increases the uptake of the dye and is hydrolyzed by 
cytoplasmic esterases to regenerate and trap the dye in the cytosol. Fura-2 free of 
Ca2+ emits fluorescence upon excitation at 380 nm but after binding to Ca2+ 
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experiences a shift to 340 nm in its excitation wavelength. Therefore, the ratio of 
fluorescence intensity obtained by excitation at 340 nm to the intensity obtained by 
excitation at 380 nm provides an accurate measurement of the free Ca2+ 
concentration.  
  
Hepes buffer, pH 7.40             
NaCl    125 mM  
KCl   3  mM  
NaH2PO4 x H2O 1.25  mM  
CaCl2 x 2H2O  2.5  mM  
MgCl2 x 6H2O  1.5  mM  
Glucose   10  mM  
HEPES    10 mM  
  
Variations in cytosolic calcium were studied in HUVECs. For this purpose, HUVECs 
were seeded in 60 mm2 dishes and grown three days to long confluence. Afterwards, 
cells were washed twice with Hepes buffer (37°C). Fura-2-AM was added in Hepes 
buffer containing 0.1% BSA to a final concentration of 1 µM and the cell suspension 
was incubated for 30 min at 37°C. After two washing steps with Hepes buffer-0.1% 
BSA, the dish with new Hepes buffer 0.1% BSA was placed on the stage of a Zeiss 
Axiovert 200 inverted microscope (Zeiss, Oberkochen, Germany) equipped with a 
Polychrome V monochromator and an IMAGO-QE camera (TILL Photonics GmbH, 
Gräfelfing, Germany). Chamber temperature was maintained at 37°C by placing the 
coverslip holder on a heating insert P (Zeiss, Oberkochen, Germany) for additional 
10 min. Cells were stimulated as indicated. Excitation wavelengths were alternately 
selected at 340 nm and 380 nm and fluorescence filtered at 510 nm (LP filter) was 
recorded. Images were acquired every 10 sec and analysed using the TILLvisION 
Software 4.0.1.2 (TILL Photonics GmbH, Gräfelfing, Germany). Areas of interest 
corresponding to the whole field of vision were selected, the background was 
subtracted and the average intensity of each area over the course of the experiment 
was recorded. Changes in ratio of fluorescence emitted by excitation at 340 and 380 
nm represent changes in the intracellular Ca2+ content. For measurement in Ca2+-
free conditions, 0.1% BSA-containing Hepes buffer without Ca2+ was used. 
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11   cAMP Enzyme-Linked Immunosorbent Assay (ELISA) 
 
The cAMP assay was performed in two steps:  we performed the accumulation of 
cAMP in intact cells, and the determination of cAMP was studied by an enzyme-
linked immunosorbant assay (ELISA) kindly performed by Prof. Dr. Hermann Ammer 
(Professor of Clinical Pharmacology, Department of Veterinary Sciences, University 
of Munich). 
Accumulation of cAMP in intact HUVECs was determined as follows: HUVECs were 
seeded in 24-well plates and grown until long confluence (3 days). Immediately 
before stimulation, cells were washed three times with 1 ml/well pre-warmed DMEM 
containing 10 mM HEPES (pH 7.4) and 0.01% BSA. Subsequently, cells were 
stimulated in a total volume of 250 µl.  Accumulation of cAMP was allowed for 15 min 
at 37°C and was terminated by the addition of 750 µl ice-cold HCl 50 mM. The 
amount of cAMP generated was determined in the supernatants by enzyme-linked 
immunosorbant assay after acetylation of the samples. 
 
12   Confocal microscopy 
 
A Zeiss LSM 510 META confocal microscope (Zeiss, Oberkochen, Germany) 
equipped with a heating stage from EMBL (Heidelberg, Germany) was used for 
obtaining images of fixed cells as well as for life cell imaging experiments. 
 
12.1 Microscopy with fixed cells 
 
HUVECs were cultured in ibidi µ-slides (8-well ibiTreat, ibidi GmbH, Munich, 
Germany) until reaching long confluency (3 days). Afterwards, cells were treated as 
indicated, washed with PBS and fixed with 4% parafomaldehyde in PBS at room 
temperature (10 min), followed by permeabilization via incubation with 0.2% Triton X-
100 (Sigma, Taufkirchen, Germany) in PBS (2 min). Cells were washed and 
unspecific binding was blocked with 0.2% BSA in PBS for 30 min. Afterwards, cells 
were incubated with the respective primary antibody for 1 h at room temperature 
(Table 4). 
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Table 4: Primary antibodies used for confocal microscopy 
 
Antigen  Isotype  Dilution  in   Provider 
VEC   mouse monoclonal 1:400  BSA 0.2 % Santa Cruz  
cortactin  rabbit polyclonal 1:400  BSA 0.2 % Cell Signaling 
phos.cortactinY421 rabbit polyclonal 1:400  BSA 0.2 % Cell Signaling 
phos. MLC T18/S19 rabbit polyclonal 1:400  BSA 0.2 % Biosource 
phos. PKA-sub. rabbit monoclonal 1:400  BSA 0.2 % Cell Signaling 
phos. VASPS157 rabbit polyclonal 1:400  BSA 0.2 % Cell Signaling 
p65   rabbit polyclonal 1:400  BSA 0.2 % Santa Cruz  
 
Following three washing steps with PBS, cells were incubated with the respective 
secondary antibodies or with rhodamin/phalloidin for staining of F-actin, respectively, 
for 45 min at room temperature (Table 5). 
 
Table 5: Secondary antibodies/dye used for confocal microscopy 
 
Antibody/Dye    Dilution  in   Provider 
AlexaFluor® 488 goat-anti-mouse  1:400  BSA 0.2 % Molecular Probes 
AlexaFluor® 488 goat-anti-rabbit  1:400  BSA 0.2 % Molecular Probes 
AlexaFluor® 647 chicken-anti-rabbit 1:400  BSA 0.2 % Molecular Probes 
AlexaFluor® 633 goat-anti-mouse  1:400  BSA 0.2 % Molecular Probes 
Rhodamin/phalloidine    1:400  BSA 0.2 % Molecular Probes 
 
Finally, preparates were again washed three times with PBS (5 min) and embedded 
in FluorSave aqueous mounting medium (VWR, Darmstadt, Germany). 
 
12.2 Live cell imaging 
 
Live cell imaging was performed to visualize the dynamics of single cells during 
cytoskeleton rearrangement. HUVECs were transfected with 5 µg of the indicated 
plasmid. After transfection, HUVECs were seeded into ibidi µ-slides (8-well ibiTreat, 
300,000 cells per well). A time series was collected by taking images every 30 sec 
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(10 min ahead and 30 min after stimulation). LSM Image Browser (Zeiss) was used 
for analysis of images.  
 
13   Flow cytrometry  
 
Flow cytometry (FACS) allows counting, sorting, and analysis of various parameters 
of single cells or particles suspended in a fluid. Each cell passes a focused laser 
beam and scatters the illuminating light. If particles have previously been stained with 
a fluorescent dye, fluorescence emission occurs and can be detected. 
Flow cytometry has been used for the analysis of intercellular adhesion molecule-1 
(ICAM-1) expression. All measurements were performed on a FACSCalibur (Becton 
Dickinson, Heidelberg, Germany). Cells were illuminated by a blue argon laser (488 
nm). 
Cells were seeded in 12-well plates and grown to confluence and either left untreated 
or preincubated with WS® 1442 for 24h. After stimulation with TNFα (10 ng/ml) for 
24h, cells were harvested with T/E, washed with PBS, and fixed in PBS/4% formalin 
on ice for 10 min. Afterwards, cells were washed two times with PBS and 0.5 µg 
FITC-labeld ICAM-1 antibody (Biozol, Eching, Germany) was added for 45 min at 
21°C. Cells were washed three times and 10,000 cells were measured by flow 
cytometry to detect the membrane expression of ICAM-1 as evidenced by a median 
shift in fluorescence intensity (FL1: 509 nm) (Figure 11).  
 
untreated cells    TNFα treated cells     
 
Figure 11: Median shift of fluorescence intensity (indicates ICAM-1 cell surface expression). 
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FACS buffer (pH 7.4) 
NaCl   138.95  mM 
K2HPO4  1.91   mM 
NaH2PO4  16.55   mM 
KCl   3.76   mM 
LiCl   10.14   mM 
NaN3   3.08   mM 
Na2EDTA  0.97   mM 
H2O 
14   F-actin Quantification 
 
HUVECs were cultured to long confluence in collagen G-coated 100 mm dishes, 
treated for the indicated times, and subsequently stained with rhodamine-phalloidin 
(Molecular Probes/Invitrogen, Karlsruhe, Germany) according to the protocol of 
chapter 12.1 . Cells were washed and the bound dye was extracted from the cells 
with methanol (30 min; 4°C). The fluorescence intensity (ex: 542 nm/em: 565 nm) of 
the methanolic dye solution was measured in a fluorescence plate reader 
(SpectraFluor Plus, Tecan Deutschland GmbH). The mean fluorescence intensity of 
untreated cells was set as 100%. The data are expressed as percent increase of 
fluorescence versus the control. 
 
15   Measurement of Vascular Permeability in the Mouse Cremaster 
Muscle in Vivo  
Male C57BL/6NCrl mice (Charles River Laboratories, Sulzfeld, Germany) weighting 
23 to 25 g were used. All experiments were performed according to the German 
legislation for the protection of animal. Surgery and measurement of vascular 
permeability has been described previously. In brief, mice were anesthetized i.p. 
using a ketamine (Pfizer, Karlsruhe, Germany)/xylazine (Bayer, Leverkusen, 
Germany) mixture. Fluorescein isothiocyanate-dextran (150 kDa; Sigma-Aldrich), 
Ringer solution (control), and Crataegus special extract WS® 1442 (tanning agents-
free, bolus sufficient to reach 100 µg/ml plasma concentration), was applied into the 
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left femoral artery. 30 min after WS® 1442 application, the cremaster was superfused 
with histamine (30 µM; Sigma-Aldrich) for 10 min. Postcapillary venules with 
diameters of 18 to 30 µm were analyzed. 10 regions of interest (50 x 50 µm2) in the 
interstitial tissue (approximately 50 µm distance from the venule) were randomly 
selected. Intravital microscopy images were recorded with an IMAGO charge-
coupled device camera (TILL Photonics, Gräfelfing, Germany) and subjected to 
digital image analysis (TILLvisION 4.0; TILL Photonics). These experiments were 
kindly performed by the working group of Prof. Dr. F. Krombach at the Walter-
Brendel-Center for Experimental Medicine in Munich. 
 
16   Statistical analysis 
 
All experiments were performed at least three times unless otherwise indicated in the 
respective figure legend. Data are expressed as mean ± standard error of the mean. 
Statistical analysis was performed with SigmaStat software version 3.1 (Aspire 
Software International). Statistical tests are indicated in the figure legend. Statistical 
significance is assumed if p≤0.05. 
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III  RESULTS 
 
1   Anti-inflammatory potential of WS® 1442 on the endothelium 
 
1.1 WS® 1442 reduces TNFα induced ICAM-1 surface expression 
 
To clarify whether WS® 1442 has an anti-inflammatory potential on the endothelium, 
we measured the ability of WS® 1442 to reduce the cell surface expression of the 
intercellular adhesion molecule-1 (ICAM-1), an important marker of inflammation-
activated endothelial cells, which can be induced by the pro-inflammatory cytokine 
TNFα. Pretreatment with WS® 1442 led to a 25 % reduction of TNFα-induced ICAM-1 
expression, suggesting a protective effect of WS®1442 on the TNFα-induced 
activated endothelium (Figure 12). 
 
 
 
Figure 12: Effect of WS®1442 on the TNFα-induced ICAM-1 cell-surface expression. HUVECs were 
grown to confluence, pretreated with WS® 1442 (24 h; 10 µg/ml) in the indicated 
concentrations, followed by the treatment with TNFα (10 ng/ml; 24h). ICAM-1 cell surface 
expression was determined by FACS analysis as described in section II 13. 
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1.2 WS® 1442 does not affect NF-κB activity. 
 
The transcription factor NF-κB plays a key role in the upregulation of ICAM-1 cell 
surface expression upon TNFα signaling. In our system, TNFα-activated NF-κB is not 
influenced by the Crataegus extract WS® 1442. Figure 13 shows that WS® 1442 
neither alters the TNFα-induced increase of NF-κB DNA-binding activity (Figure 13A), 
nor the TNFα-induced p65 translocation to the nucleus (Figure 13B). This suggests 
that WS®1442 does not mediate its effect on the ICAM-1 expression via inhibition of 
NF-κB activity. 
 
A         B 
 
 
Figure 13: Influence of WS® 1442 on TNFα induced NF-κB-signaling activation. A HUVECs were 
either left untreated, treated with TNFα (10 ng/ml; 24 h), or with TNFα after preincubation 
with WS® 1442 (24 h) at indicated concentrations. NF-κB DNA-binding activity was analyzed 
by EMSA as described in section II 6. B HUVECs were left untreated (control), treated for 30 
min with TNFα (10 ng/ml), or with TNFα after preincubation with WS® 1442 (100 µg/ml; 24 h) 
(n=2; white bar = 10 µm). Immunocytochemistry of p65 and confocal microscopy were 
performed as described in section II 12.1 . 
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1.3  WS® 1442 does not affect p38 MAPK activity. 
 
Since we found that NF-κB is not influenced by WS® 1442, we analyzed the activity of 
the mitogen-activated protein kinase p38, which upregulates ICAM-1 cell-surface 
expression in response to cytokines as well.11 Treatment with WS® 1442 for 24 h did 
not change the degree in phosphorylation and therefore the activity state of MAPK 
p38, caused by TNFα (10 min). Thus, WS® 1442 does not mediate the reduction of 
ICAM-1 cell surface expression via inhibition of p38 MAPK activity  (Figure 14). 
 
 
 
Figure 14: WS® 1442 does not influence TNFα induced p38 MAPK activity. HUVECs were left 
untreated, treated with TNFα (10 ng/ml; 10 min), or with TNFα after preincubation with WS® 
1442 (24 h) at indicated concentrations. p38 MAPK phosphorylation was analyzed by 
Western blot analysis as described in section II 5. 
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1.4 WS®1442 does not affect AP-1 activity. 
 
In analogy to NF-κB, we analyzed DNA-binding activity of the third major player in 
cytokine induced ICAM-1 upregulation, the transcription factor activator protein 1 
(AP-1). Likewise, WS®1442 showed no significant reduction of the TNFα induced 
DNA binding activity of AP-1 (Figure 15). These data suggested that WS®1442 does 
not affect the TNFα-mediated AP-1 activity, and therefore, does not reduce ICAM-1 
upregulation via targeting AP-1. 
 
 
 
Figure 15: Influence of WS® 1442 on TNFα-induced AP-1 activity. HUVECs were left untreated, 
treated with TNFα (10 ng/ml; 24 h) or with TNFα after preincubation with WS® 1442 (24 h) in 
the indicated concentrations. AP-1 DNA-binding activity was analyzed by EMSA as 
described in section II 6. 
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2   Effects of WS®1442 on endothelial hyperpermeability 
 
2.1 Inhibition of inflammation-induced endothelial hyperpermeability in vitro 
 
Besides the upregulation of ICAM-1, hyperpermeability is a clear indicator of 
inflammatory activation of the endothelium. In order to test if WS®1442 has a 
protective potential, we treated HMECs with thrombin, a well-characterized and 
potent inducer of endothelial barrier disruption, after preincubation with WS® 1442. 
The macromolecular permeability-increase was analyzed via detection of the amount 
of FITC-labeled dextran diffusion through a HMEC monolayer. Figure 16A shows a 
clear concentration dependent decrease of macromolecular endothelial permeability. 
1-100 µg/ml of WS® 1442 (30 min) significantly reduces macromolecular 
permeability. The time course (Figure 16B) points out that WS® 1442 (100 µg/ml) 
protects the endothelium during the whole 30 min of stimulation with thrombin. These 
findings demonstrate for the first time that WS® 1442 is a highly potent protective 
compound that affects the inflammation induced macromolecular permeability 
increase. For further experiments a concentration of 100 µg/ml was used. 
 
A 
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Figure 16: WS® 1442 blocks the increase in thrombin-induced hyperpermeability in a time and 
concentration dependent manner. A Concentration dependency: HMECs were left untreated, 
treated with thrombin (1 U/ml; 30 min), or with thrombin after preincubation with WS® 1442 
(30 min) at indicated concentrations. B Time dependency: HMECs were left untreated, 
treated with thrombin (1 U/ml), or with thrombin after preincubation with WS® 1442 (100 
µg/ml). Macromolecular permeability was measured as described in section II 9. 
 
2.2  Inhibition of endothelial permeability in vivo 
 
As an ultimate in vivo proof of the barrier protective properties of WS®1442, the 
measurement of macromolecular permeability at the mouse cremaster muscle model 
was used. Because of the prothrobotic activity of thrombin we used histamine for 
endothelium activation. Histamine was superfused on the cremaster muscle for 10 
min, after pretreatment with WS® 1442 (30 min). The extravasation into the 
surrounding tissue after histamine treatment could be detected as a strong increase 
in fluorescence (Figure 17B). In comparison to treatment with histamine alone, 
WS®1442 significantly minimized macromolecule extravasation (Figure 17A). These 
in vivo data pointed out that WS®1442 clearly protects the endothelial barrier function 
against an inflammation-induced activation. 
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B 
       
 
Figure 17: Effect of WS® 1442 on the inflammation-induced endothelial permeability in vivo 
measurement. A: 30 min after bolus treatment with WS® 1442 to reach 100 µg/ml plasma-
concentration, histamine (50 µM) was superfused on the cremaster muscle for 10 min. We 
compared animals treated with histamine, with animals treated with histamine after 
pretreatment with WS® 1442. Fluorescence signal was measured right before histamine 
treatment (t=0) and 30 min later. B: Representative fluorescence images of the post-capillary 
venues. In vivo macromolecular permeability assay was performed as described in section II 
15. 
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2.3  WS® 1442 modulates key parameters of endothelial permeability 
 
In order to figure out the underlying signaling mechanism of WS®1442 to protect 
endothelial barrier function, we focused on the key parameters of endothelial 
permeability. We had a look on the disruption of adhesion junctions, on cell-
contraction and on the rearrangement of the actin cytoskeleton, which represent the 
three core events governing endothelial hyperpermeability, caused by inflammatory 
mediators like thrombin. 
 
2.3.1 WS®1442 prevents the disruption of adhesion junctions 
 
The inflammatory activation of the endothelium by thrombin (30 min) led to a 
disassembly of the adhesion junctions, with strong changes in morphology from a 
regular to a fringy and porous VEC seam, resulting in inter-endothelial gaps. This 
change is visualized in a histogram showing the fluorescence increase of VEC, giving 
the VEC protein levels along the white bar, which crosses two sites of cell-cell 
contacts (Figure 18). In this histogram, a properly formed cell-cell adhesion zone 
(untreated cells) is indicated as a single high and sharp peak. In contrast, a series of 
undefined 3 to 5 small peaks indicate the thrombin-activated unshaped and stretched 
VEC border. WS® 1442 itself does not affect the VEC border. Pretreatment with WS® 
1442 completely abolished deleterious effects of thrombin, characterized by the 
sharp and high peak (Figure 18). Adhesion junctions show smooth and uninterrupted 
VEC borders, indicating that there are no tending forces between single cells. These 
images visualized that WS® 1442 pretreatment protect cells from thrombin induced 
morphological changes. 
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Figure 18: VEC seem protection by WS®1442 preincubation on thrombin activated endothelial cells. 
HUVECs were left untreated, treated with thrombin (1 U/ml; 30 min), or with thrombin after 
preincubation with WS®1442 (100 µg/ml; 30 min). Immunocytochemistry of VEC and 
confocal microscopy were performed as described in section II 12.1 Small white bar = 10 
µm. One representative image out of 6 independently performed experiments is shown, 
each. 
 
2.3.2 WS® 1442 prevents the translocation of adhesion junction proteins to the 
cytosol 
 
According to the microscopic approach, the thrombin-induced endothelial barrier 
disruption was detected by a translocation of VEC from the cell membrane into the 
cytosol. WS® 1442 treatment totally blocked this translocation and therefore VEC 
internalization. Although the protein content of β-catenin and p120ctn in the cytosol 
did not increase after thrombin treatment, they were reduced after WS® 1442 
treatment (Figure 19). These results show that the adhesion molecule VEC itself, and 
additionally its two major regulatory proteins as well, are protected by WS® 1442, 
underlining the above described morphological barrier protective effect of WS®1442. 
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Figure 19: WS® 1442 affects thrombin-induces translocation of AJ complex proteins to the cytosol. 
HUVECs were left untreated, treated with thrombin (1 U/ml; 30 min), or with thrombin after 
preincubation with WS® 1442 (100 µg/ml; 30 min). Membrane fractionation and Western blot 
analysis was performed as described in section II 3.2 and II 5. 
 
2.3.3 WS® 1442 prevents VEC tyrosine-phosphorylation 
 
In the next step we intended to figure out if WS® 1442 affects the tyrosine-
phosphorylation of VEC induced by thrombin leading to AJ complex dissociation. 
Especially the phosphorylation site Y 731 correlates with endothelial hyper-
permeability.18 Figure 20 displays a strong induction of tyrosine 731 phosphorylation 
by thrombin, which was abolished by the treatment with WS® 1442. Our data show 
that WS® 1442 inhibits VEC activation. 
 
 
 
Figure 20: WS® 1442 inhibits the thrombin-induced VECY731 phosphorylation. HUVECs were grown to 
confluence, were left untreated, treated with thrombin (1 U/ml; 30 min), or with thrombin after 
preincubation with WS® 1442 (100 µg/ml; 30 min). Protein sample preparation and Western 
blot analysis were performed as described in section II 3.1 and II 5. 
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2.3.4 WS® 1442 modulates the actin cytoskeleton 
 
The second key parameter of inflammation-induced endothelial activation, leading to 
hyperpermability is the rearrangement of the actin cytoskeleton into stress fibers. 
Treating HUVEC with thrombin induced the formation of stress fibers. Pretreatment 
with WS® 1442 showed a complete inhibition of the cell spanning stress fiber 
formation. Interestingly WS® 1442 induced the formation of cortical actin, which is 
known to correlate with reduced endothelial permeability (Figure 21A). In order to 
measure the actin polymerization necessary for stress fiber formation, we 
biochemically quantified the formation of F-actin (Figure 21B). The induction of F-
actin polymerization was significantly reduced by WS® 1442. As Figure 21 shows, 
WS® 1442 not only inhibits the formation of permeability-inducing stress fibers, but 
also evokes barrier-stabilizing cortical actin in the endothelium. Both effects are 
mediated by different signaling pathways, we therefore hypothesized that WS® 1442 
has not just an anti-inflammatory action, but also activates barrier protective signaling 
pathways per se. 
 
A 
 
B 
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Figure 21: Modulation of the actin cytoskeleton by WS® 1442. A HUVECs were grown to confluence, 
were left untreated, treated with thrombin (1 U/ml; 30 min), or with thrombin after 
preincubation with WS® 1442 (100 µg/ml; 30 min). F-actin staining and confocal microscopy 
were performed as described in section II 12.1 White bar = 10 µm (control). One 
representative image out of 6 independently performed experiments is shown, each. B  F-
actin quantification. HUVECs were grown to confluence, were left untreated, treated with 
thrombin (1 U/ml; 30 min), or with thrombin after preincubation with WS® 1442 (100 µg/ml; 30 
min). F-actin staining and quantification were performed as described in section II 14. 
 
2.3.5 Live cell imaging of actin showed the formation of cortical actin by WS® 1442 
 
To observe the cortical actin formation by WS® 1442 and to get an idea of the time 
flow of this process we performed actin live cell imaging microscopy (Figure 22). 
After 2 min of treatment with WS® 1442 the increase of actin at the cell membrane 
gets obvious. Actin polymerizes directly at the cell membrane, there is no transport of 
polymerized actin to the cell membrane. Finally, after 10 min the maximum in cortical 
actin formation has been reached. 
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Figure 22: Live cell imaging of cortical actin induction by WS® 1442. WS® 1442 (100 µg/ml) was 
applied for 10 min. Cell transfection and life cell imaging was done according to section II 7 
and II 12.2  
 
 
 
 
 
 
Results 
 
54 
2.3.6 WS® 1442 prevents the activation of cell contraction 
 
Furthermore, we examined the influence of WS® 1442 on inflammation-induced 
endothelial cell contraction, the third key parameter of endothelial permeability. In the 
interplay between AJ disruption and actin rearrangement, cell contraction leads to 
inter-endothelial gap formation. Figure 23A shows the strong thrombin effect on the 
phosphorylation of myosin light chain 2 (MLC2), colocalized at the stress fibers, 
indicating the activation of cell contraction. In the microscopic approach as well as in 
the biochemical Western blot analysis, the extract clearly minimized the 
phosphorylation of MLC2 (Figure 23A/B). In consequence, these data suggest that 
WS® 1442 inhibits inflammation-induced cell contraction.  
 
A 
 
 
B 
 
 
Figure 23: WS® 1442 inhibits thrombin induced MLC2 phosphorylation. HUVECs were grown to 
confluence, were left untreated, treated with thrombin (1 U/ml; 30 min), or with thrombin after 
preincubation with WS® 1442 (100 µg/ml; 30 min). A Immunocytochemistry of ppMLC and 
confocal microscopy were performed as described in section II 12.1 . White bar = 10 µm. 
One representative image out of 3 independently performed experiments is shown, each. B 
Protein sample preparation and Western blot analysis was performed as described in 
section II 3.1 and II 5. One representative image out of 3 independently performed 
experiments is shown, each. 
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2.4 NO does not affect the protective effect of WS® 1442 on the endothelial 
barrier function 
2.4.1 The inhibition on the EHP by WS® 1442 is independent from NO  
 
To analyze whether WS® 1442 affects endothelial barrier function by regulating NO-
signaling we tested the effect of WS® 1442 and L-NAME (a NO synthase inhibitor) on 
the macromolecular permeability in vitro. L-NAME did not influence the barrier-
protective effect of WS® 1442 (Figure 24), indicating that WS® 1442 works NO 
independently. This experiment was kindly performed by Elisabeth Willer. 
 
 
Figure 24: WS® 1442-induced macromolecular permeability decrease is NO independent. HMECs 
were treated with thrombin after preincubation with WS®1442 (100 µg/ml; 30 min) and 
additionally combined with or without 60 min preincubation of the NO synthase inhibitor L-
NAME (100 µM). The in vitro macromolecular permeability assay was performed as 
described in section II 9. 
 
2.4.2 WS® 1442 affects the key parameters of endothelial permeability NO 
independent. 
 
After we could show that eNOS-inhibition did not alter the effects of WS®1442 on 
macromolecular permeability, we wanted to clarify if the key parameters of 
endothelial permeability also unaltered in the presence of L-NAME. Inhibition of the 
NO-synthase did not alter the influence of WS® 1442 on stress-fiber formation as well 
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as the stabilization of AJ. Hence, WS®1442 affects AJ and the actin cytoskeleton NO-
independently. 
 
 
 
Figure 25: AJ and f-actin modulation by WS® 1442 is NO independent. HUVECs were grown to 
confluence, were left untreated, treated with thrombin (1 U/ml; 30 min), or with thrombin after 
preincubation with WS® 1442 (100 µg/ml; 30 min), combined with or without 60 min 
preincubation of the NO synthase inhibitor L-NAME (100 µM). F-actin staining and confocal 
microscopy were performed as described in section II 12.1 White bar = 10 µm (control). One 
representative image out of 3 independently performed experiments is shown, each.  
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Figure 25 continued 
 
 
2.5  WS® 1442 inhibits the inflammatory Ca2+-signaling 
 
Since we found that WS® 1442 blocks EHP in functional permeability assays and 
affects key parameters of endothelial permeability, we wanted to investigate which 
part of the upstream thrombin signaling is affected. Ca2+ is important for relaying 
signals of different EHP-inducing agents in the endothelium, leading to EC rounding 
and therefore to inter-endothelial gap formation, which is inevitably correlated to 
changes in endothelial permeability. We aimed to figure out if WS® 1442 affects the 
inflammatory Ca2+-signaling at the endothelium. 
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2.5.1 WS®1442 inhibits the long lasting Ca2+-signal of thrombin 
 
The [Ca2+]i-increase was induced by thrombin treatment. The thrombin-dependent 
raise of [Ca2+]i is very fast and strong at the beginning, but declines after 2 to 3 min to 
reach a plateau phase of low magnitude, that lasts for a minimum of 15 min. 
Preincubation with WS® 1442 blocked this long-lasting Ca2+ signal, which is crucial 
for the activation of many Ca2+ downstream targets (Figure 26A).16 The fast [Ca2+]i 
response directly following thrombin administration is not affected. Comparing the 
areas under the curve (AUCs) of these [Ca2+]i measurements, WS® 1442 significantly 
lowers the total [Ca2+]i-increase down to the basal level (Figure 26B). 
 
A 
 
B 
 
 
Figure 26: WS® 1442 inhibits the sustained Ca2+ signaling of thrombin-induced endothelial cells. 
HUVECs were grown to confluence, were left untreated, treated with thrombin (1 U/ml; 30 
min) after preincubation with WS® 1442 (100 µg/ml; 30 min). [Ca2+]i was detected by 
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fluorescence microscopy using Fura-2, as described in section II 10. A Time course of the 
Ca2+ measurement (15 min), thrombin vs. WS®1442 + thrombin. B AUC diagram of the Ca2+ 
measurement (15 min), thrombin vs. WS®1442 + thrombin. 
 
2.5.2 WS® 1442 inhibits thrombin-induced extracellular Ca2+ influx 
 
The [Ca2+]I increase induced by thrombin is composed of two different phases: The 
first increase by the release of intracellularly stored Ca2+ and the second phase, the 
long lasting [Ca2+]i-increase, by extracellular influx of Ca2+. To clarify if WS® 1442 
inhibits the extracellular Ca2+-influx, as discriebed by the previous findings, we 
repeated the experiment (2.5.1), but treated the cells with WS® 1442 not until the long 
lasting Ca2+-plateau has been reached (after 4 min of thrombin treatment). WS® 1442 
suddenly blocks the extracellular Ca2+-influx down on control level (Figure 27A).  
To clarify if WS®1442 selectively inhibits the extracellular Ca2+ influx, we performed 
the assay in a Ca2+-free HEPES-buffer, treated the cells with thrombin (see section 
2.5.1), and added (t = 4 min) 2 mM Ca2+ to the cells. Until Ca2+ treatment, the cells 
showed no Ca2+ plateau, and behave like WS®1442 pretreated cells, similar to 2.5.1 
(Figure 27). This fact indicates that WS® 1442 modulates the Ca2+ signal of thrombin 
by inhibition of the extracellular Ca2+ influx. After Ca2+ treatment, the cells without 
WS®1442 form a normal Ca2+ plateau, in contrast to WS®1442 treated cells, which 
Ca2+ signal again decreases after 4 min. These data further support the hypotheses, 
that WS®1442 selectively inhibits the extracellular Ca2+ influx. 
 
A 
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Figure 27: Measurement of the thrombin-induced inhibition of Ca2+- nflux by WS® 1442. A Time course 
of HUVECs grown to long confluence treated with thrombin ( t= 0 min; 1 U/ml; 14 min) after 
treatment with WS® 1442 (t=4min; 100 µg/ml). B Time course of HUVECs grown to long 
confluence treated with thrombin (t=0min; 1 U/ml; 14 min) after preincubation with WS® 1442 
(30 min; 100 µg/ml) in Ca2+ free HEPES-buffer. At t = 4 min 2 mM Ca2+ was added to the 
cells. In both experiments, [Ca2+]i was detected by fluorescence microscopy using Fura-2 as 
described in section II 10 (n=2). 
 
 
2.5.3 WS®1442 does not lead to Ca2+ store depletion  
 
To exclude that preincubation with WS®1442 does lead to Ca2+ store depletion, we 
compared the effect of WS®1442 treatment with that of thapsigargin, an inhibitor of 
the sarco/endoplasmatic reticulum Ca2+ ATPase, which is and known to induce Ca2+ 
store depletion and in consequence a reduction of EHP.16 Thapsigargin raised 
intracellular Ca2+ first in an initial peak, but later on continuously, which indicates a 
Ca2+ store depletion. In contrast, WS® 1442 treatment reduced [Ca2+]i at the 
beginning, but after 4 min the cells showed no difference in [Ca2+]i increase to 
untreated cells (Figure 28). These findings pointed out that, WS®1442 does not lead 
to Ca2+ store depletion in endothelial cells.  
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Figure 28: Time course of the measurement of [Ca2+]i after treatment with WS® 1442 compared to 
thapsigargin. HUVECs were grown to long confluence, left untreated, treated with WS® 1442 
(t = 0min; 100 µg/ml) or with thrombin after preincubation with WS® 1442 (100 µg/ml; 30 
min). [Ca2+]i was detected by fluorescence microscopy using Fura-2 as described in section 
II 10 (n=2). 
 
 
2.5.4 WS®1442 inhibits the activation of PKC 
 
We next investigated whether the inhibition of the sustained Ca2+ signal by WS® 1442 
modifies the downstream effectors of Ca2+ signaling. Protein kinase C (PKC) has 
been shown to mediate the induction of stress fiber formation and cell contraction.19 
For analyzing the activity of PKC we looked at the phosphorylation site at PKC 
(T514) itself and at the phosphorylation of the PKC ((R/K)X(S*)(R/K)) substrate 
motive, both correlating with conventional PKC activity. As expected, thrombin 
activated PKC itself and induced the phosphorylation of its downstream targets. 
WS®1442 pretreated cells showed no raise in phosphorylation of PKC or PKC 
substrates (Figure 29). According to these findings, we assume that WS® 1442 
affection of the sustained Ca2+ signal, inhibits the Ca2+ downstream target PKC.19 But 
a direct inhibition of PKC could not be excluded. 
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Figure 29: WB analysis of the inhibition of conventional PKC by WS® 1442 in inflammatory conditions. 
HUVECs were grown to confluence, were left untreated, treated with thrombin (1 U/ml; 30 
min), or with thrombin after preincubation with WS® 1442 (100 µg/ml; 30 min). Protein 
sample preparation and Western blot analysis was performed as described in section II 3.1 
and II 5. 
 
2.5.5 WS® 1442 inhibits thrombin-induced RhoA activation 
 
In analogy to the experiments regarding the inhibition of PKC activity, we checked 
whether WS® 1442 treatment also effects a major regulator of stress fiber formation, 
the small GTPase RhoA. Thrombin is known to activate RhoA in the endothelium, 
which induces the formation of stress fiber.4 WS® 1442 totally blocks thrombin-
induced Rho activation (Figure 30). 
 
 
 
Figure 30: The inhibition of inflammation-induced RhoA activity. HUVECs were grown to confluence, 
were left untreated, treated with thrombin (1 U/ml; 30 min), or with thrombin after 
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preincubation with WS® 1442 (100 µg/ml; 30 min). RhoA GTPase activation assay and 
Western blot analysis was performed as described in sections II 8, and II 5. 
 
2.6 Activation of the barrier protective cAMP signaling by WS® 1442  
 
Restoring the endothelial barrier function by controlling the inflammatory Ca2+-
signaling is an obvious and promising approach. In addition to the inhibition of the 
inflammatory barrier disruption, the activation of a per se barrier-stabilizing pathway 
also represents a promising approach. cAMP signaling is known as a strong 
stabilizer of the endothelial barrier (see section I 3). The first evidence that cAMP 
signaling might participate in the endothelial barrier stabilization by WS® 1442, could 
be noticed by the cortical actin formation (seen in IV 2.3.4), which is known to be 
cAMP-dependent. Therefore we hypothesized that WS® 1442 activates the barrier 
stabilizing cAMP signaling pathways. 
 
2.6.1 WS® 1442 increases endothelial cAMP 
 
We aimed to clarify if WS® 1442 increases cellular cAMP levels in cultured 
endothelial cells. The cAMP levels were measured by an enzyme-linked 
immunosorbant assay. Figure 31 shows that WS® 1442 concentration dependently 
increases the leves of cellular cAMP. WS® 1442 significantly raises cAMP in 
endothelial cells at 10 and 100 µg/ml. For further analysis of Crataegus influenced 
cAMP-dependent signaling-pathways we used 100 µg/ml extract. 
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Figure 31: WS® 1442 increases cAMP levels concentration dependently in endothelial cells. HUVEC 
were grown to long confluence, either left untreated or treated for 15 min with the indicated 
WS® 1442 concentrations. cAMP levels were measured by ELISA according to section II 11. 
*, p ≤ 0.001 versus control (= 100%) (n=4). 
 
2.6.2 Cause of WS® 1442-induced [cAMP]i increase 
 
To clarify whether the cAMP increase is due to an activation of the adenylate cyclase 
(AC), or due to an inhibition of cAMP degradation via phosphodiesterases (PDE), we 
treated HUVECs with WS®1442 together with forskolin (AC activator) or IBMX (PDE 
inhibitor) (Figure 32). Additional cAMP increase could only be reached by a 
combination of forskolin together with WS®1442. Because forskolin induces maximal 
AC activity, Crataegus could only led to a further raise of forskolin-induced cAMP 
levels by inhibition of cAMP degradation. According to that finding, IBMX does not 
alter the WS®1442-induced cAMP increase at all, suggesting that WS®1442 leads to 
an inhibition of PDE. 
 
 
 
Figure 32: Crataegus inhibits cAMP degradation. HUVECs were grown to long confluence, either left 
untreated or treated with WS®1442 (100 µg/ml; 15min) or cotreated with forskolin (10 µM) or 
IBMX (500 µM) as indicated. cAMP levels were measured by ELISA according to section II 
11. cAMP levels of control cells were set as 100% (n=2). 
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2.6.3 Induction of PKA activity by WS® 1442 
 
We investigated whether the cAMP-dependent protein kinase A (PKA) pathway, of 
which the activity correlates with an inhibition of EP, is involved in mediating the WS® 
1442 evoked barrier protection. We monitored PKA activation via determination of 
the phosphorylation of PKA substrates. Forskolin was used as a positive control. 
WS® 1442 raises PKA-substrate phosphorylation, but to a lower content than 
forskolin (Figure 33A). However, the WS® 1442-induced increase in phosphorylation 
is localized at the cell membrane and is comparable to that of the cAMP analogue 8-
Br-cAMP (Figure 33B). These data suggest that WS® 1442 increases PKA activity at 
the cell membrane. 
 
A 
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Figure 33: WS® 1442 induces PKA activity at the cell membrane. HUVECs were grown to long 
confluence, either left untreated or were treated with WS®1442 (30 min, 100 µg/ml) or 
forskolin (30 min, 1 µm), or 8-Br-cAMP (30 min, 100 µM). A Protein sample preparation and 
Western blot analysis was performed as described in section II 3.1 and II 5. B 
Immunocytochemistry of phos. PKA-substrates and confocal microscopy were performed as 
described in section II 12.1 . White bar = 10 µm (control). One representative image out of 3 
independently performed experiments is shown, each. 
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2.6.4 VASP activity-induction by WS®1442  
 
Since we found that PKA is activated by WS® 1442, we investigated downstream of 
PKA, if the cytoskeletal adaptor protein VASP is activated as well. Active VASP is 
phosphorylated at Ser157. WS® 1442 induced VASP phosphorylation and therefore 
led to activation of VASP (Figure 34A). In addition, the increase of phosphorylated 
VASP could be detected exclusively at the cell membrane (Figure 34B). In contrast to 
that, the positive control forskolin strongly induces VASP phosphorylation mainly in 
the cytosol. These data suggest that WS® 1442 activates VASP at the cell 
membrane. 
 
A 
 
 
B 
 
 
Figure 34: The induction of VASP activation by WS® 1442 at the cell membrane. HUVEC were grown 
to long confluence, either left untreated or were treated with WS® 1442 (30 min, 100 µg/ml) 
or forskolin (30 min, 1 µm). A Protein sample preparation and Western blot analysis was 
performed as described in section II 3.1 and II 5. B Immunocytochemistry of pVASP and 
confocal microscopy were performed as described in section II 12.1 . White bar = 10 µm 
(control). One representative image out of 3 independently performed experiments is shown, 
each. 
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2.6.5 The induction of barrier protection by WS®1442 is PKA independent. 
 
Next, we wanted to clarify if PKA is involved in the WS® 1442-evoked barrier 
protection. Therefore, we modified the macromolecular permeability assay and 
preincubated the cells with the PKA inhibitor cAMPS-Rp. In this new setting WS® 
1442 still clearly reduced the permeability increase (Figure 35A). Cells treated with 
WS® 1442 showed no significant difference to PKA-inhibited cells. In Figure 35B 
demonstrates that PKA activity was completely inhibited by cAMPS-Rp. This results 
point out that WS® 1442-induced barrier protection is PKA independent. 
 
A 
 
B 
 
 
Figure 35: The inhibition of the endothelial hyperpermeability by WS® 1442 is PKA independent. A 
HMECs were left untreated, treated with thrombin (1 U/ml) or with thrombin after 
preincubation with WS®1442 (100 µg/ml; 30 min). Cells were additionally pretrated with the 
PKA inhibitor cAMPS-Rp (100 µM; 60 min). The permeability increase of WS® 1442 vs. 
thrombin was set as 100%. Macromolecular permeability assay was performed as described 
in section II 9. B HUVEC were grown to long confluence, left untreated, treated with 8-Br-
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cAMP (30 min, 100 µM) or in combination with 30 min preincubation with cAMPS-Rp (100 
µM). Protein sample preparation and Western blot analysis was performed as described in 
section II 3.1 II 5.  
 
2.6.6 The induction of Rap1 by WS® 1442 
 
Since we found that WS®1442 does not mediate its effect via activation of PKA, we 
wanted to figure out if the barrier-protective and cAMP-induceable Rap1pathway is 
activated by WS® 1442. In a Rap1 activation pull-down assay, WS®1442 was able to 
strongly activate Rap1 (Figure 36), which is known to be a central regulator of AJ 
formation and maintenance.  
 
 
 
Figure 36: The induction of Rap1 by WS®1442 activates Rap1. HUVECs were grown to long 
confluence, either left untreated or were treated with WS®1442 (30 min, 100 µg/ml). Rap1 
pull-down assay was performed according to section II 8. 
 
2.6.7 The induction of Rac1 by WS®1442 
 
The GTPase Rac1 is one of the downstream targets of Rap1 signaling and a main 
regulator of the cytoskeleton, but is also involved in AJ stabilization. Figure 37 shows 
the strong activation of Rac1 by WS®1442 treatment. 
 
 
 
Figure 37: WS®1442 activates Rac1. HUVEC were grown to long confluence, either left untreated or 
were treated with WS®1442 (30 min, 100 µg/ml). Rac1 pull-down assay was performed 
according to section II 8. 
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2.6.8 The induction of cortactin activation by WS®1442 
 
In a third step we observed the activation of cortactin, a downstream target of Rac1. 
As an actin binding protein, activated cortactin is known to mediate the cortical actin 
rearrangement. Its activity can be displayed by Tyr421-phosphorylation.68 WS® 1442 
induces cortactin phosphorylation after 5 min, and sustained it during the period of 
preincubation with WS® 1442 (Figure 38A). By CLSM we found that phosphorylated 
cortactin is colocalized with cortical actin at the cell borders (Figure 38B). These 
experiments show that treatment with WS® 1442 activates cortactin at the cell border. 
 
A 
 
B 
 
 
Figure 38: Cortactin activation at the cell border by WS® 1442. A HUVECs were grown to long 
confluence, left untreated or treated with WS® 1442 (100 µg/ml) for the indicated time points. 
Protein sample preparation and Western blot analysis was performed as described in 
section II 3.1 II 5. B HUVECs were grown to long confluence, left untreated or treated with 
WS® 1442 (100 µg/ml; 30 min). Immunocytochemistry and confocal microscopy were 
Results 
 
70 
performed as described in section II 12.1 . White bar = 10 µm (control). One representative 
image out of 5 independently performed experiments is shown, each. 
 
2.7 Protection of the endothelial barrier function by WS® 1442 fractions  
 
Since we found several actions of WS® 1442 on the inflammatory EP signaling, we 
wanted to figure out whether specific actions could be associated to single WS® 1442 
fractions. Therefore, we repeated several key experiments with four different WS® 
1442 fractions (described in section II 1.1 ).  
 
2.7.1 WS® 1442 fractions 32-36 inhibit endothelial hyperpermeability. 
 
First of all, we wanted to clarify which fraction shows EHP-inhibiting properties. 
Therefore we performed the macromolecular permeability in vitro assay. Fractions 
32-36 reduced significantly the thrombin-induced hyperpermeability increase (Figure 
39). Fraction 30 does not have a barrier protective potential. These data clearly 
demonstrate that there must be more then one active component in the total WS® 
1442 extract.  
 
 
 
Figure 39: Inhibition of EHP by the WS® 1442 fractions 32-36 in vitro. HMECs were left untreated, 
treated with thrombin (1 U/ml) or treated with thrombin after preincubation with WS® 1442 
fractions 32-36 (single concentrations are calculated on 100 µg/ml of the total extract; 30 
min). Macromolecular permeability assay was performed as described in section II 9.
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2.7.2 WS® 1442 fractions 32-36 affect the key parameters of endothelial permeability 
 
In analogy to the experiments with the total WS® 1442 extract, we now wanted to figure 
out if and how these active fractions target the key parameters of EHP. The Western 
blot analysis of phosphorylated VEC showed a protective effect of WS® 1442 fractions 
34 and 36. The phosphorylation of MLC2 was reduced to control level only by fraction 
32 (Figure 40A). 
Congruent to these findings, fraction 30 did not inhibit the activation of the monolayer by 
thrombin as we could see by CLSM (Figure 40B). However, fraction 32 showed an 
obvious reduction of stress fibers and a less fringy VEC seam indicating a reduced cell 
contraction. Fraction 34 exhibited the strongest morphological protection of the 
monolayer. There are no intercellular gaps, no fringy seams, and no stress fibers. 
Additionally, fraction 34 induced cortical actin and cortactin translocation to the cell 
membrane as well. Fraction 36 did not protect the VEC seam, from stress-fiber 
formation. Importantly, we found that each of the WS® 1442 fractions targets a different 
spectrum of key parameters.  
 
A 
 
 
Figure 40 A/B: Different WS® 1442 fractions target different key parameters of EHP. HUVECs were grown 
to confluence, left untreated, treated with thrombin (1 U/ml; 30 min) or treated with thrombin 
after preincubation with WS® 1442 fractions (single concentrations are calculated on 100 µg/ml 
of the total extract; 30 min) A Protein sample preparation and Western blot analysis was 
performed as described in section II 3.1 II 5. B Immunocytochemistry and confocal microscopy 
were performed as described in section II 12.1 . White bar = 10 µm (control). One 
representative image out of 3 independently performed experiments is shown, each. 
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Figure 40B 
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2.7.3 WS® 1442 fraction 32 modified the thrombin-induced [Ca2+]i increase 
 
Next we intended to figure out which fractions influence the [Ca2+]i signal . Interestingly, 
only fraction 32 changed the initial thrombin-induced [Ca2+]i signal , but did not inhibit 
the long lasting [Ca2+]i signal for the whole measurement, compared to the total WS® 
1442 extract (Figure 41). 
 
 
 
Figure 41: WS® 1442 fraction 32 modifies the thrombin-activated [Ca2+]i signal. HUVECs were grown to 
long confluence, were treated with thrombin (1 U/ml; t = 0) after preincubation of WS® 1442 
fractions (single concentrations are calculated on 100 µg/ml of the total extract; 30 min). [Ca2+]i 
was detected by fluorescence microscopy using Fura-2 as described in section II 10. Basal 
[Ca2+]i was set as 100%, the [Ca2+]i-increase is shown [%]; (n = 3). 
 
2.7.4 Inhibition of RhoA activation by WS® 1442 fraction 30 and 32 
 
To study if the affection of the [Ca2+]i signal by WS® 1442 fraction 32, or a [Ca2+]i signal 
independent affection by WS® 1442 fraction 30, 34, and 36 inhibits central downstream 
targets of the [Ca2+]i signaling pathway, we analyzed their effects on RhoA in an RhoA 
activation pull down assay. Congruent to Ca2+ measurements (see 2.7.3), WS® 1442 
fraction 32, inhibited the thrombin-induced activation of RhoA (Figure 42), which could 
be explained by the modulation of the [Ca2+]I signal. The WS® 1442 fraction 34 and 36 
exhibited no effect on RhoA-activation. WS® 1442 fraction 30, which showed no effect 
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on the macromolecular permeability increase, completely blocked the activation of 
RhoA. These are preliminary data and have to be corroborated by further experiments. 
 
 
 
Figure 42: Inhibition of RhoA activation by WS® 1442 fraction 30 and 32. HUVECs were grown to long 
confluence, were treated with thrombin (t = 0min; 1 U/ml; 14 min) or with thrombin after 
preincubation of the WS® 1442 fractions (single concentrations are calculated on 100 µg/ml of 
the total extract) preincubation. RhoA activation assay and Western blot analysis was 
performed as described in sections II 8/II 5 (n = 1). 
 
2.7.5 The increase of cAMP level by WS® 1442 fraction 34 and 36 
 
Besides targeting the Ca2+ signaling, WS®1442 increases cellular cAMP-levels. The 
preliminary cAMP-measurements of the WS® 1442 fractions showed that fraction 34/36 
significantly increased cAMP levels (Figure 43). 
 
 
 
Figure 43: The increase of cAMP by WS® 1442 fraction 34 and 36. HUVECs were grown to long 
confluence, either left untreated or treated for 15 min with WS® 1442 fraction (single 
concentrations are calculated on 100 µg/ml of the total extract). cAMP levels were measured by 
ELISA according to section II 11 (n = 2). 
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2.7.6 WS® 1442 fraction 34 and 36 influence the PKA dependent activation of VASP 
 
Since we found a cAMP increase evoked by fraction 34/36 we wanted to clarify if the 
downstream targets of the cAMP signaling are affected, too. According to the previous 
findings, PKA dependent VASP was activated after treatment with WS® 1442 fraction 34 
and 36 (Figure 44). WS® 1442 fraction 30 and 32 showed a slight increase. 
 
 
 
Figure 44: VASP is activated by the WS® 1442 fraction 34 and 36. HUVECs were grown to long 
confluence, either left untreated or were treated with WS® 1442 fraction (30 min; single 
concentrations are calculated on 100 µg/ml of the total extract). Protein sample preparation and 
Western blot analysis was performed as described in section II 3.1 II 5 (n = 2). 
 
2.7.7 The activation of Rac1 by WS® 1442 fraction 30 and 34 
 
The downstream effector of the Epac1/Rap1-signaling, Rac1, regulates cortical actin 
formation and AJ complex stabilization. A clear activity induction is caued by fraction 34 
as expected by the cAMP-increasing action of this fraction. Surprisingly WS®1442 
fraction 36 showed no activation, although we found a cAMP increase. WS®1442 
fraction 30 on the contrary, does not induce cAMP, but activates Rac1 (Figure 45).  
 
 
 
Figure 45: Rac1 is activated by fraction 30 and 34. HUVECs were grown to long confluence, either left 
untreated or were treated with WS® 1442 fraction (30 min; single concentrations are calculated 
on 100 µg/ml of the total extract). Rac1 pull-down assay was performed according to section II 8 
(n = 1). 
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2.7.8 The increase in cortactin activation by WS®1442 fraction 34 
 
Cortactin as an effector of the Rac1 signaling is crucial for cortical actin formation. WS® 
1442 fraction 34 shows a strong activation of cortical actin by increasing 
phosphorylation localized at the cell membrane. WS® 1442 fraction 36 shows similar 
effects, but to a lesser degree. Fraction 30 and 32 showed no difference to the control 
cells. These data suggest that cAMP-inducing fractions, especially the fraction 34, 
mediate the cytoskeleton rearrangement to cortical actin in the preincubation period, 
which stabilizes the endothelial barrier function. 
 
Figure 46: Fraction 34 and 36 induce phosphorylation of cortactin and induce cortical actin formation. 
HUVECs were grown to confluence, left untreated or with 30 min WS® 1442 fractions (single 
concentrations are calculated on 100 µg/ml of the total extract) preincubation. 
Immunocytochemistry and confocal microscopy were performed as described in section II 12.1 . 
Small white bar = 10 µm (control). One representative image out of 3 independently performed 
experiments is shown, each. 
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Figure 46 
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IV  DISCUSSION 
 
This work presents a novel mode of action for the well-established Crataegus extract 
WS®1442: Crataegus inhibits inflammation-induced endothelial hyperpermeability and 
therefore beneficially affects the endothelial barrier function. To understand the 
relevance of this action it is important to know that endothelial hyperpermeability is a 
hallmark of endothelial inflammation leading to endothelial dysfunction. This mechanism 
takes part in the pathophysiology of a multitude of diseases (Figure 47). In most of the 
common human vascular diseases there is an inflammatory response of the 
endothelium to stress, prolonging the activation of the endothelium.69 The inductors of 
endothelial stress are identical to the known risk factors for CVD: arterial hypertension, 
smoking, high blood cholesterol levels, or diabetes mellitus, which are all associated 
with the release of proinflammatory cytokines (e.g., IL-6, TNFα) and a consecutive 
induction of a systemic inflammatory state.70-73 Bonetti et al. and de Jager et al. linked 
the exposure of CVD risk factors to the impairment of endothelial function,74, 75 which 
again leads to the progression to CVD.5, 76-80 Hence anti-inflammatory therapies 
became more and more important for patients suffering from CVD, especially 
atherosclerosis, and started with the use of statins.81, 82 In recent years, agents 
interfering with TNFα, interleukin-1, and leukotriene pathways are evaluated in clinical 
trials for patients suffering from coronary artery disease.83 Even the immunosuppressive 
drug methotrexate will be tested for the secondary prevention in patients suffering from 
CHF.84 But beside this central role of endothelial dysfunction in CVD and many other 
diseases, this cell layer is not amenable to traditional physical diagnostic maneuvers of 
inspection. Therefore, other organs or clinical parameters are in the focus in patient 
monitoring or in evaluating the pathophysiology of diseases. The endothelium has been 
out of the focus as a potential drug target for a long time period. But now great efforts 
are done to find successful novel therapy options. These efforts point out that there is 
an enormous need for new tools to target inflammation-induced endothelial activation. 
Thus, the endothelium still has an immense untapped potential as a therapeutic target. 
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This work is divided into two parts, both of them focusing on one distinct mechanism of 
inflammatory endothelial activation:  
 
(I) the endothelial ICAM expression 
(II) the endothelial permeability increase 
 
 
Figure 47: Overview of the participation of endothelial dysfunction in the pathophysiology of a multitude of 
disease. 
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1 Effect of WS® 1442 on ICAM-1 expression 
 
The inflammatory response is the stereotyped reaction of the body to tissue damage. 
Beside rapid and transient delivery of soluble elements from the blood to the site of 
injury, there is a more prolonged transmigration of leukocytes to the tissue.85 
Leukocytes have to be recruited to the site of inflammation, a process guided by 
cytokines. Subsequently, they attach to the vessel wall, where they are locomoted to 
the endothelial cell borders to migrate through the endothelium into the inflammatory 
interstitial tissue.86 This transendothelial migration or diapedesis represents the “point of 
no return” in the context of inflammatory response. The inflammatory endothelial 
activation is a pivotal step to prepare the endothelium for leukocyte adhesion by the 
expression of CAM on the surface of EC. But this mechanism is not only initiated by 
tissue damage, it also occurs as a response of the endothelium to stress, e.g. shear 
stress in hypertension, leading in consequence to local inflammatory reactions and has 
been implicated in the pathophysiology of many CVD.87  
To reveal a potential of WS® 1442 to inhibit distinct steps of endothelial activation, we 
analyzed the impact of the Crataegus extract WS® 1442 on inhibiting ICAM-1 cell 
surface expression. This is a common and very specific marker for inflammatory 
endothelial activation.88,89 Corresponding to Leeuwenberg et al. we used TNFα to 
induce ICAM-1 expression in HUVECs.89 The TNFα-induced expression of ICAM1 was 
reduced about 25% by WS® 1442.  
To elucidate the mechanism of WS®1442 to reduce TNFα induced ICAM-1 expression, 
we focused on the three central pathways responsive to an induction of stress stimuli 
and cytokines: the c-Jun N-terminal kinases (JNKs) pathway, the p38 mitogen-activated 
protein kinase (p38 MAPK) pathway, and the NFκB pathway.14 The DNA-binding activity 
of AP-1 or NFκB to the ICAM-1 promotor sequence induced by TNFα was not affected 
by preincubation with WS®1442. Additionally translocation of the p65 subunit of NFκB to 
the nucleus was not influenced by WS® 1442. Also the activation of the p38 MAPK-
signaling seems not to be a target of WS® 1442 action. These findings point out that the 
reduction of ICAM-1 cell surface expression is not due to the inhibition of these distinct 
targets. WS®1442 seems to interfere other downstream targets of TNFα leading to an 
inhibition of ICAM-1 expression. To determine whether the effects of WS® 1442 were 
specific to adhesion molecule expression or rather to cytokine-induced gene expression 
in general further experiments have to be done. But before the exact signaling 
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mechanism of this effect will be analyzed the relevance of this effect hast to be 
characterize (diapedesis of leukocytes). Gerritsen et al. showed a similar effect of the 
flavonoid apigenin on TNFα induced ICAM-1 expression.90 Apigenin showed no effect 
on the activation of the transcription factor NF-KB (nuclear translocation or binding to 
the consensus oligonucleotide), but they found a inhibitory effect on the transcriptional 
activation of NF-KB (reporter gene assay). 
 
1.1  Conclusion 
 
WS® 1442 showed a weak effect on a central marker of inflammatory endothelial 
activation, the expression of ICAM-1 on the cell surface. However, WS® 1442 had no 
influence on some of the major pathways leading to ICAM-1 expression. This suggests 
that WS® 1442 might influence ICAM-1 cell surface expression distal of the analyzed 
targets, or WS® 1442 targets a further TNFα-induced signal pathway. Thus, there are 
still interesting aspects, which might open a new field of research connected to the 
diapedesis of leukocytes and WS®1442: 
 
(I) Is a reduction of 25% of TNFα-induced ICAM-1 expression on cell surface by 
WS®1442 sufficient to decrease the diapedesis of leukocytes from the blood 
vessels to the tissue in vivo? Taking into account that most of the leukocytes 
that once initiated contact with the endothelium at sites of inflammation lose 
the adhesion contact and reenter the circulation,85 25% less ICAM-1 would 
possibly be enough for a significant reduction in diapedesis. For this purpose 
it would be interesting to analyze leukocyte diapedesis in vivo (e.g. intravital 
microscopy).91  
(II) To what extend is the vascular cell adhesion molecule (VCAM) affected by 
WS®1442? VCAM governs transendothelial migration, and is vital in the 
mechanism of diapedesis of leukocytes through the endothelium.92 
 
 
 
 
 
Discussion 
 
82 
2  Effects of WS® 1442 on inflammation-activated endothelial hyper-
permeability 
 
Endothelial barrier dysfunction is responsible for protein-rich tissue edema, which is a 
significant pathogenic component in multiple diseases, such as atherosclerosis93, 
cardiovascular disease,12 acute lung injury,94 or sepsis.54 Treatment with diuretics 
represents the standard therapy of edema.95 Inflammation plays a crucial role in edema 
formation and inflammation-induced hyperpermeability showed up to be the capable 
target to affect edema.5, 6, 83 The screening for novel permeability-inhibiting compounds 
has recently been intensified focusing on the discovery of lead structures that affect 
aberrant inflammation-induced endothelial hyperpermeability. We investigated the effect 
of WS® 1442 on inflammation-induced endothelial hyperpermeability, by two different 
settings: 
 
(I) As prove of principle the macromolecular vascular permeability in the mouse 
cremaster muscle in vivo.  
(II) The measurement of endothelial macromolecular permeability in vitro was 
used as a basal functional assay for analyzing the underlying signaling 
mechanisms. 
 
WS® 1442 clearly inhibited the barrier disruption in vivo induced by histamine (90% 
reduction) - a strong mediator of endothelial permeability increase. The histamine-
induced permeability increase in mice pretreated with WS® 1442 was not significantly 
different from the control animals. If we compare these findings with those of the atrial 
natriuretic peptide (ANP) done in the same setting (60% reduction), WS® 1442 showed 
a much stronger effect on endothelial hyperpermeability.96 This difference in effect 
intensity might be due to the affection of different targets. Also in vitro WS® 1442 was 
able to completely block the endothelial permeability induced by thrombin, the best 
characterized mediator of endothelial hyperpermeability, down to control levels.  
In conclusion of these findings, we could exhibit for the first time that WS® 1442 is a 
strong protector of endothelial barrier function in vivo and in vitro. Thus, we found not 
only a new extracardial function of WS® 1442 involved in the control of CHF symptoms, 
but also elucidated an action, which is discussed to affect the underlying mechanisms of 
CHF pathophysiology. Therefore, WS® 1442 might be beneficial for CHF prevention. 
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2.1 Influence of WS® 1442 on endothelial hyperpermeability signaling 
 
To understand how WS® 1442 interferes with the mechanisms of endothelial 
hyperpermeability we observed the underlying signaling cascades. A short pretreatment 
with WS® 1442 (30 min) lead to a barrier protection, suggesting that WS® 1442 might 
directly affect the underlying signaling mechanism. Promising targets for beneficially 
influencing endothelial hyperpermeability (EHP) are the central signaling molecules of 
the pathways leading to the activation of the three key parameters of endothelial 
permeability:23 Cytoskeletal protein reorganization, activation of the contractile 
machinery and disassembly of VEC complex (AJ),23 all depending on the change of 
intracellular Ca2+ concentrations.21, 97  
 
2.1.1 WS® 1442 and the key parameters of the endothelial permeability 
 
We examined potential effects of WS® 1442 on these three key parameters of EHP. 
Interestingly, WS® 1442 affected all these three key systems: adherent junctions 
disassembly, cell contraction, and the cytoskeleton rearrangement. WS® 1442 inhibited 
the thrombin-induced inflammatory endothelial activation.17, 18, 98-101 Live cell imaging of 
the cytoskeleton showed increased cortical actin formation after treatment with WS® 
1442, known to be barrier protective and AJ stabilizing.17, 101 
It is obvious that WS® 1442 affects EHP-signaling upstream of the key parameters. This 
regulation of endothelial permeability indicates that there might be a central step 
affected by WS® 1442 in EHP signaling, such as the Ca2+-signaling, which plays a 
central role in the acute inflammation-induced endothelial activation.  
 
2.1.2 WS® 1442 and Ca2+ signaling in endothelial hyperpermeability 
 
Almost every permeability-increasing mediator raises intracellular Ca2+ levels.16, 19 
Therefore, it seems of special interest to clarify if WS® 1442 targets the thrombin 
induced [Ca2+]i increase. Thrombin increases [Ca2+]i within two distinct phases.102,26 
WS® 1442 completely inhibited the increase in [Ca2+]i in the second sustained phase, 
the first phase stayed unaffected. In cardiac myocytes, Crataegus raises [Ca2+]i cAMP-
independently by inhibition of the Na+/K+-ATPase, which leads to the positive inotropic 
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effect.44 However, there exists no data describing the regulation of Ca2+ signaling in the 
endothelium. Interestingly, the sustained second phase of thrombin-induced [Ca2+]i 
increase is known to be mediated by store-operated cation channels (SOCs: TRP1 and 
TRP2). Moreover, thrombin induced endothelial hyperpermeability, MLC2 
phosporylation, and stress-fiber formation are based on the opening of TRP1 and 
TRP2. 19, 25, 26, 103, 104 We could exclude that WS® 1442 mediates the inhibition of the 
second phase of [Ca2+]i increase via Ca2+ store depletion, and seems to be causing  a 
direct inhibition of the Ca2+ influx into the cytosol of the second phase. Therefore, we 
hypothesize that WS®  1442 mediates its Ca2+ effect via SOC inhibition. 
In the next step we wanted to figure out if this inhibition of the second phase of [Ca2+]i 
increase affects the key parameters of EHP. The activation of the Ca2+ dependent 
protein kinase C (PKC) isoform PKCα leads to the disassembly of the VEC junctional 
complex and to the activation of the small Rho GTPase RhoA.104, 105 RhoA is the central 
regulator of stress fiber formation, it inactivates MLCP resulting in contraction of 
endothelial cells.106 PKCα as well as RhoA are activated by thrombin. In WS®1442 
pretreated cells the thrombin-induced PKC and RhoA activation is completely blocked. 
These findings indicate, that the action of WS®1442 affects both of these central 
signaling parameters.  
 
The impact of WS® 1442 on the key parameters of EP and therefore on the endothelial 
permeability itself seems to be due to the modulation of the Ca2+-signaling (PKC and 
RhoA inhibition). Interestingly, until now, permeability-inhibiting compounds, which 
affect these targets, are very rare. Moreover, they are, with only few exceptions, not 
effective, unselective, or too toxic for therapeutical use. For instance, inhibitors of MLCK 
that prevent MLC phosphorylation, failed to completely abolish the hyperpermeability 
response107. Fusadil, a ROCK inhibitor,108 showed permeability inhibiting characteristics 
in vitro109. However, in vivo data or clinical studies are missing up to now. In initial 
studies, Ruboxistaurin, an inhibitor selective for the PKCβ isoform, decreased the 
development of sight-threatening macula edema110. Nevertheless, most inflammatory 
edema correlate with an activation of PKCα and not PKCβ and a total block of PKCα 
can activity increases basal endothelial permeability as well32. The approach to affect 
single targets in Ca2+ signaling seems not to be effective enough to completely prevent 
inflammation induced vascular leakage. Barrier protective signaling cascades have to 
be activated as well. In this regard, WS® 1442 showed beside its inhibitory potential on 
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Ca2+ signaling an effect, connected to endothelial barrier protection, the cortical actin 
arrangement. 
 
2.1.3 WS® 1442 and the barrier protective cAMP-signaling  
 
A further promising strategy for an anti-hyperpermeability therapy is to target barrier 
stabilization signaling pathways, which antagonize vascular leakage and protect 
endothelial barrier function. It is assured that cAMP elevating drugs like Beraprost108 
and the atrial natiuretic peptide96, 111reduce inflammation-induced permeability and 
edema-formation.28-31 In contrary, EHP-increasing mediators, such as thrombin reduce 
basal cAMP levels in the cell.112  
 
cAMP exerts its effect primarily via direct activation of protein kinase A (PKA) and of the 
guanine nucleotide exchange factor Epac1, an activator of Rap1. Both pathways are 
parallel and independent of each other.113 Additionally, it is known that the formation of 
cortical actin is a cAMP-dependent process.19 Even though there are citations claiming 
Crataegus extracts as a cAMP-raising herbal remedy, until now, there exists no 
publication showing that WS® 1442 increases cAMP levels. Only an inhibition of isolated 
PDE was shown once. 114 
 
In order to clarify the involvement of WS® 1442 in cAMP signaling, endothelial cAMP 
levels were measured. We showed for the first time that WS® 1442 raises the cAMP 
content in endothelial cells. Therefore, a participation of the cAMP-dependent barrier 
protective signaling seems to be obvious. How does WS® 1442 increase cAMP levels, 
by activation of AC or by inhibition of PDE? Based on our findings, we hypothesized 
that Crataegus raises cAMP by an inhibition of PDE. There are several strong hints 
emphasizing this hypothesis: (I) WS® 1442 shows slower kinetics for maximum increase 
of cAMP than it is known for AC agonists. (II) The WS® 1442–induced increase of cAMP 
could not be forced up by additional PDE inhibition via IBMX. However, the forskolin-
induced cAMP increase via AC activation was elevated by WS® 1442 pretreatment. (III) 
WS® 1442 selectively increases the activation of the Rap1-pathway via cAMP. This 
specificity of the second messenger cAMP to activate a distinct signaling pathway is 
regulated by individual PDE isoforms, modulating distinct signaling pathways in the cell, 
provided by their remarkably selective cellular and sub-cellular localization,115 and only 
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subsidiary by ACs. (IV) Inhibitors of the PDE2 isoform decrease endothelial permeability 
in inflammatory conditions.116 Accordingly, TNFα induces vascular leakage via 
increasing PDE2A expression 117. PDE are known targets for the treatment of EHP. 
Although selective PDE2 inhibitors are available, clinical studies, which evaluate the 
therapeutic efficiency of these compounds, are still missing.116  
In the present work we could show that WS® 1442 activates PKA and its downstream 
target VASP. However, the inhibition of PKA showed no significant influence on the 
WS®1442 mediated barrier protection in vitro. Therefore, we excluded the PKA 
signaling pathway to be the main target of WS® 1442 in the regulation of EHP inhibition. 
We next focused on the Epac1 downstream effector Rap1, the most important regulator 
of AJ stability and cortical actin formation.27, 34, 41, 118, 119 WS® 1442 showed up to be a 
strong activator Rap1/Rac1/cortatcin signaling cascade.68, 120 Beside the effect on Ca2+ 
signaling, WS® 1442 posseses a second strong effect on the activation of the Rap1-
signaling pathway, which is in the focus of today’s EHP research. 
 
2.1.4 NO and the WS® 1442 barrier protective signaling  
 
As WS® 1442 is known to increase endothelial NO formation, which can regulate 
endothelial permeablity.19 We could exclude that NO formation,121,58 is responsible for 
the barrier protective effects of WS® 1442.122 Upon cotreatment with NO-synthase 
inhibitor, WS® 1442 still exhibited its barrier protective properties. Moreover 
morphological changes like cortactin activation and cortical actin formation induced by 
WS® 1442 were not affected by NO synthase inhibition.  
 
2.1.5 Effects of WS® 1442 fractions on the barrier protective signaling 
 
To clarify if the effect of WS® 1442 on the Ca2+ and the cAMP signaling is due two 
separate actions, based on different components of the total extract, and to get further 
hints which chemical class of biological compounds mediate this effects, we used four 
fractions of WS® 1442. We repeated the in vitro key experiments, which were used to 
analyze the signaling-pathways regarding endothelial hyperpermeability. The following 
Figure 48 shows a summary of these experiments and displays the effects of each 
fraction.  
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 WS® 1442 fractions 
Effects on thrombin induced endothelial cell activation  30 32 34 36 
inhibition of macromolecular permeability     
inhibition of intracellular Ca2+-increase     
inhibition of MLC phosphorylation      
inhibition of VEC phosphorylation      
inhibition of AJ-disruption      
inhibition of stress-fiber formation      
inhibition of RhoA activity      
     
Effects on cAMP signaling 30 32 34 36 
increase of cellular cAMP-concentration      
phosphorylation of PKA-substrat      
induction of VASP phosphorylation      
activation of Rac1     
formation of cortical actin      
induction of cortactin phosphorylation      
 
Figure 48: Summary of all experiments done with WS® 1442 fractions. Active WS® 1442 fractions in each 
experiment setting were marked in green. Some of the experiments have to be regarded as 
preliminary data (s. Results). 
 
After analyzing the activity pattern of the single WS® 1442 fractions they can be divided 
into groups by there potential to target distinct pathways. The first group consists of, 
WS®1442-fraction 32, containing mainly flavones and flavonols, and mediates the 
inhibition of the thrombin-induced [Ca2+]i increase and of its downstream targets (cell 
contraction, AJ and actin-cytoskeleton). The second group fraction, 34 and 36, contains 
mainly oligomeric procyanidines of different polymerization degree and mediates the 
effects on the cAMP signaling. WS® 1442 fraction 34 showed generally stronger effects 
than 36. These data clearly proved that WS® 1442 mediates two independent effects. 
Both of them lead to the same result, the inhibition of the thrombin-induced endothelial 
permeability. These completely different signaling cascades, which of course can 
influence each other, complement one another, leading to that strong impact of WS® 
1442 on endothelial hyperpermeability. These two effects might explains the difference 
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between ANP and WS® 1442 in the effect intensity on EHP in vivo. Althought both affect 
all of the key parameters of endothelial permeability, WS® 1442 in contrast to ANP does 
additionally affect the Ca2+ signaling cascade.96, 111 
These findings also consort with the data from experimental literature. Oligomeric 
procyanidines of different origin showed permeability- and edema-inhibiting effects in 
vivo. Fitting to our data, a correlation between the polymerization degree and the effect 
intensity was found. A reduced polymerization degree (n) increases the effect, as seen 
with WS® 1442 fractions 34 (n= 1-4) and WS® 1442 fractions 36 (n>4).123, 124 Also 
flavanoids showed anti-edema effects in venous disease, which are strongly related to a 
inflammatory pathogenesis.125  
 
2.2 Conclusion 
 
Our work showed that Crataegus extract WS® 1442 is highly barrier protective. It inhibits 
the inflammation-induced endothelial permeability increase in vivo and in vitro. Thus, we 
present a completely new extracardiac effect of this well studied drug, in addition to the 
previous known WS® 1442 functions related to the treatment of CHF. Inflammation-
induced endothelial activation is discussed to take part in CVD-pathophysiology. 
Because of its direct intervention with inflammatory endothelial activation, WS®1442 
might be a new therapeutic option for the prevention of CVD, and would perfectly 
complement existing drugs, with an impact on basal anti-inflammatory mechanisms in 
CVD. 
Moreover, we elucidated the underlying mechanisms. If we compare the mechanisms of 
WS® 1442 to other substances affecting the endothelial hyperpermeability signaling 
pathway, the particular benefit of WS® 1442 is to target all of the key parameters leading 
to EHP in two different modalities: The inflammatory activation of the endothelium by 
Ca2+/PKC/RhoA signaling, and the activation of the highly barrier protective 
cAMP/Rap1/Rac1 signaling pathway. These pathways were affected at a very early and 
essential signaling step, complementing one another in handling vascular 
permeability.94, 126 This character is unique compared to other hyperpermeability-
inhibiting compounds, and it is likewise conceivable that it enables WS® 1442 to flexibly 
inhibit the induction of vascular leakage by a wide range of different permeability-
inducing mediators, which is of importance to handle such a complex mechanism like 
EHP. Each of these two effects can be related to distinct WS® 1442 fractions, and is 
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therefore related to different chemical classes of bioactive compounds including 
flavonoids or oligomeric procyanidins. Certainly, this multi-component character of 
WS®1442 is comparable to the principle of modern combinatory drug therapies: causing 
synergistic effects by multi-targeting, which is doubtless an advantage for the 
prevention of such complex dysfunctions, such as inflammatory vascular leakage, and 
is not at all a handicap of a herbal remedy extract. In addition, the safety of WS®1442 is 
proved in several studies and centuries of therapeutical use.  
 
3 Possible aspects of future research 
 
Certainly it will be a long way to close the gap between these findings and drug 
targeting, between bench and bedside. Although these data show a great potential in 
controlling endothelial permeability also in vivo, the question if these effects are 
appropriate in CVD prevention or in the control of inflammation-induced edema, will be 
one possible aspect of future research.  
 
The main questions are: 
(I) What are the active compounds in these WS® 1442 fractions? To answer this 
question, further sub fractionations are needed to reduce the number of 
compounds, to isolate and test some of the candidates separately of each 
other. These single compounds could be the source to characterize new 
leading structures for EHP targeting. 
(II) Are there further cell targets involved, which could lead to further effects? For 
example effects on tight junctions, integrins or microtubuli. 
(III) Does WS® 1442 influence processes, that are based on related signaling 
mechanisms, such as leukocyte transmigration through the endothelium85 or 
vascular endothelial growth factor-induced brain edema formation after 
ischemic stroke.127  
(IV) What is the exact mechanism of WS® 1442 to inhibit the Ca2+ increase and to 
increase cAMP levels? 
(V) Does WS® 1442 possess potential to prevent CVD, e.g. in an atherosclerotic 
model? 
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V   SUMMARY 
 
WS® 1442 and endothelial ICAM expression 
 
This study shows for the first time that WS® 1442 exerts anti-inflammatory effects. WS® 
1442 reduced the expression of ICAM-1 on the surface of endothelial cell. Based on 
these findings, further investigations into the anti-inflammatory profile of WS® 1442 
would be highly interesting. 
 
WS® 1442 and inflammation-induced endothelial hyperpermeability 
 
WS® 1442 is successfully used in the treatment of CHF. We found a completely new 
extracardial effect of the Crataegus extract WS® 1442 on the endothelial permeability 
induction, which is a hallmark of inflammation activated endothelial cells and a crucial 
mechanism in the pathophysiology of cardiovascular diseases. This study we for the 
first time elucidates that WS® 1442 blocks inflammation-induced endothelial dysfunction 
in vivo and in vitro. WS® 1442 affects all three key parameters of endothelial 
permeability: cell contraction, rearrangement of the actin cytoskeleton, and disruption of 
adhesion junctions ( 
Figure 49). WS® 1442 strongly protects endothelial barrier function by two distinct 
mechanism: 
 
(I) WS® 1442 inhibits the thrombin-induced sustained Ca2+ increase. It blocks 
the activation of MLC2, which leads to an inhibition of cell contraction. It 
abolishes activation of PKC and thus the disruption of adhesion junctions. 
WS® 1442 also affects the activation of RhoA resulting in reduced stress fiber 
formation and sustained MLC2 phosphorylation. 
(II) WS® 1442 activates the barrier protective cAMP signaling. WS® 1442 
activates two barrier stabilizing pathways. It activates PKA and its 
downstream effector VASP. The more pronounced effect, however, is the 
activation of the Ras like GTPase Rap1 by WS® 1442. This results in a 
stabilization of the VEC-complex and therefore of the adhesion junctions. 
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Additionally, via Rap1, WS® 1442 mediates the activation of Rac1 leading to 
the formation of cortical actin, resulting in a stabilization of AJ as well. 
(III) WS® 1442 mediates these two independent effects via different chemical 
classes of biological compounds, which are contained in two different 
fractions.  
 
The unique feature of WS®1442 is that it is on the one hand an inhibitor of inflammation-
induced hyperpermeability and on the other hand a stabilizer of endothelial barrier 
function. 
 
 
  
Figure 49: Summary of barrier stabilizing signaling cascades of the Crataegus extract WS® 1442.
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VI  ANP 
 
The cardiovascular hormone atrial natriuretic peptid (ANP) has been recognized to 
possess important additional functions beyond blood pressure regulation: ANP is 
expressed by macrophages and is able to influence these immune cells by attenuating 
their inflammatory response (Kiemer et al., 2005) Thus, we proposed the working 
hypothesis that ANP could open new therapeutical options for protecting against 
endothelial barrier dysfunction. In fact, some evidence is given from in vitro and ex vivo 
experiments that ANP influences an inflammation-increased permeability (Inomata et a., 
1987; Lofton et al., Kiemer et al., 2002a). However, data precisely demonstrating a 
beneficial effect of administrated ANP on inflammatory-induced endothelial barrier 
dysfunction in vivo were lacking. Moreover, data concerning the effect of ANP on 
subcellular systems that control permeability were missing. 
 
Therefore, we analyzed the in vivo barrier protective potential, and figured out the sub 
cellular targets of ANP: adherens junctions and the contractile apparatus. We could 
show that ANP is an interesting pharmacological compound opening a new therapeutic 
option for the prevention of vascular leakage.  
 
This study was completed in 2007 and published as an accelerated communication in 
Mol. Pharmacol. in 2008: 
 
Fürst R, Bubik MF, Bihari P, Mayer BA, Khandoga AG, Hoffmann F, Rehberg M, 
Krombach F, Zahler S, Vollmar AM. Atrial natriuretic peptide protects against histamine-
induced endothelial barrier dysfunction in vivo. Mol Pharmacol. 2008;74(1):1-8. 
 
The manuscript of this publication is subsequently added.  
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Abstract 
 
Endothelial barrier dysfunction is a hallmark of many severe pathologies including sepsis or 
atherosclerosis. The cardiovascular hormone atrial natriuretic peptide (ANP) has increasingly 
been suggested to counteract endothelial leakage. Surprisingly, the precise in vivo relevance of 
these observations has never been evaluated. Thus, we aimed to clarify this issue and, 
moreover, to identify the permeability-controlling subcellular systems that are targeted by ANP. 
Histamine was used as important pro-inflammatory, permeability-increasing stimulus. 
Measurements of FITC-dextran extravasation from venules of the mouse cremaster muscle and 
rat hematocrit values were performed to judge changes of endothelial permeability in vivo. 
Importantly, ANP strongly reduced the histamine-evoked endothelial barrier dysfunction in vivo. 
In vitro, ANP blocked the breakdown of transendothelial electrical resistance (TEER) induced by 
histamine. Moreover, as judged by immunocytochemistry and Western blot analysis, ANP 
inhibited changes of vascular endothelial (VE)-cadherin, !-catenin, and p120ctn morphology, VE-
cadherin and myosin light chain 2 (MLC2) phosphorylation, and F-actin stress fiber formation. 
These changes seem to be predominantly mediated by the natriuretic peptide receptor (NPR)-A, 
but not by NPR-C. In summary, we revealed ANP as a potent endothelial barrier protecting 
agent in vivo and identified adherens junctions and the contractile apparatus as subcellular 
systems targeted by ANP. Thus, our study highlights ANP as an interesting pharmacological 
compound opening new therapeutic options for preventing endothelial leakage. 
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The endothelium crucially participates in the regulation of important physiological functions, 
such as blood pressure, coagulation, or host defense, and it represents a barrier that controls 
the passage of cells, macromolecules, and fluid between the blood and the adjacent tissue 
interstitium. Beyond its physiological role, the endothelium is also involved in pathological 
conditions: Endothelial barrier dysfunction is a hallmark of inflammatory processes and still 
poses an important therapeutical challenge, since a causal pharmacological treatment is as yet 
widely lacking. 
Endothelial barrier function is mainly governed by the balance between interendothelial cell 
adhesion. Adherens junctions (AJs) are important subcellular structures responsible for 
endothelial cell-cell attachment and they represent multiprotein complexes that consist of 
vascular endothelial (VE)-cadherin, !-catenin, and p120ctn. Under inflammatory conditions VE-
cadherin junctions disassemble, thus facilitating paracellular passage, and show an increased 
tyrosine phosphorylation. Endothelial cell retraction is caused by the activation of the contractile 
machinery, i.e. the interaction between actin and myosin, which is controlled by phosphorylation 
of the myosin light chain (MLC). These two regulatory systems could be targets of a successful 
therapeutic principle. 
The cardiovascular hormone atrial natriuretic peptide (ANP) is secreted by the cardiac atria as 
response to an increased plasma volume. In general, ANP binds to the guanylate cyclase-
coupled natriuretic peptide receptor (NPR)-A and NPR-C, which lacks guanylate cyclase 
function. ANP exerts a hypotensive effect by its natriuretic, diuretic, and vasodilating action. The 
role of ANP as an important regulator of the cardiovascular system is highlighted by the fact that 
ANP (carperitide, HANP®) has been approved as drug for the treatment of acute heart failure in 
Japan. Recently, however, ANP has been recognized to possess important additional functions 
beyond blood pressure regulation: ANP is expressed by macrophages and is able to influence 
these immune cells by attenuating their inflammatory response (Kiemer and Vollmar, 2001). 
Most importantly, ANP exerts anti-inflammatory properties in the endothelium (Kiemer et al., 
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2005). Thus, we posed the working hypothesis that ANP could open new therapeutical options 
for protecting against endothelial barrier dysfunction. In fact, some evidence is given from in 
vitro and ex vivo experiments that ANP influences an inflammation-increased permeability 
(Kiemer et al., 2002a; Lofton et al., 1991; Inomata et al., 1987). However, data precisely 
demonstrating a beneficial effect of administered ANP on inflammation-induced endothelial 
barrier dysfunction in vivo are lacking. Moreover, data concerning the effect of ANP on 
subcellular systems that control permeability are missing. 
Therefore, aim of the study was (i) to examine the in vivo potential of ANP as pharmacological 
agent counteracting endothelial leakage and (ii) to investigate the influence of ANP on key 
regulators of endothelial permeability, i.e. the endothelial cell adhesion (VE-cadherin) and 
contraction system (MLC). 
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Materials and Methods 
 
Measurement of vascular permeability in the mouse cremaster muscle in vivo. Male 
C57BL/6NCrl mice (Charles River, Sulzfeld, Germany) with 23-25 g bodyweight were used. All 
experiments were performed according to the German legislation for the protection of animals. 
Surgery was performed as described by Baez (Baez, 1973). Vascular permeability was 
analyzed according to Hatekeyama et al. (Hatakeyama et al., 2006). Briefly, mice were 
anesthetized i.p. using a ketamine (Pfizer, Karlsruhe, Germany)/xylazine (Bayer, Leverkusen, 
Germany) mixture. Fluorescein isothiocyanate-dextran (150 kDa, Sigma-Aldrich, Taufkirchen, 
Germany), Ringer solution (control) and ANP (bolus sufficient to reach 200 nM plasma 
concentration, AnaSpec/MoBiTec, Göttingen, Germany) were applied into the left femoral 
artery. 20 min after ANP application, the cremaster was superfused with histamine (30 !M, 
Sigma-Aldrich) for 10 min. Dexamethasone 21-phosphate (disodium salt, Sigma-Aldrich) was 
administered i.p. (10 mg/kg bodyweight) 2 h before histamine. Postcapillary venules with 
diameters of 18-30 !m were analyzed. Ten regions of interests (50x50 !m") in the interstitial 
tissue (approx. 50 !m distant from the venule) were randomly selected. Intravital microscopic 
images were recorded with an IMAGO S/N 382KLO345 CCD-camera (TILL Photonics, 
Gräfelfing, Germany) and subjected to digital image analysis (TILLvisION 4.0, TILL Photonics). 
 
Measurement of rat hematocrit. Male Sprague-Dawley rats (Charles River) with 190-240 g 
bodyweight were used. All experiments were performed according to the German legislation for 
the protection of animals. Rats were anesthetized i.p. using a fentanyl (Jansen-Cilag, Neuss, 
Germany)/midazolam (Ratiopharm, Ulm, Germany) mixture and anesthesia was maintained by 
1.5% isoflurane (Abbott, Wiesbaden, Germany). Rats were pre-treated for 15 min with ANP 
(bolus sufficient to reach 200 nM plasma concentration) or PBS, followed by histamine (bolus 
sufficient to reach 1 !M plasma concentration). Reagents were applied into the jugular vein. 30 
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min after administration of histamine, blood samples were collected via a jugular artery catheter 
and hematocrit was determined by centrifugation in hematocrit capillaries. 
 
Cell culture. Human umbilical vein endothelial cells (HUVECs) were prepared as previously 
described (Kiemer et al., 2002a) and cultured in Endothelial Cell Growth Medium (Provitro, 
Berlin, Germany) containing 10% FBS (Biochrom, Berlin, Germany). Cells were used for 
experiments at passages 1-3. 
 
Measurement of transendothelial electric resistance (TEER). HUVECs were cultured on 
collagen A (Biochrom)-coated Millicell 12 mm PCF inserts (Millipore, Schwalbach, Germany). 
TEER measurements were performed with an Ussing-type chamber. The incubation fluid 
(HEPES-buffer containing 10% FBS) was circulated by means of humidified air streams at 
37°C. A custom-built voltage/current clamp unit in connection with a computer-aided evaluation 
program was used. Bidirectional square current pulses of 50 !A and 200 ms duration were 
applied across the monolayer every 2 second. The resistance of the monolayer was calculated 
by Ohm’s law from the induced deflection of the transendothelial voltage. 
 
Immunocyto/histochemistry and confocal laser scanning fluorescence microscopy. 
HUVECs were cultured on collagen-treated !-Slides (ibidi, Martinsried, Germany). The NPR-A/B 
antagonist HS-142-1 (Morishita et al., 1991) was kindly provided by Dr. Y. Matsuda, Kyowa 
Hakko Kogyo Co., Ltd. (Shizuoka, Japan). cANP was from Bachem (Weil am Rhein, Germany). 
HUVECs and samples of the mouse cremaster muscle (immediately dissected after histamine 
treatment) were analyzed immunocyto/ histochemically and by confocal fluorescence 
microscopy as previously described (Fürst et al., 2005). The following antibodies and reagents 
were used: mouse monoclonal anti-VE-cadherin (Santa Cruz, Heidelberg, Germany), rabbit 
polyclonal anti-phospho-Tyr731-VE-cadherin (Biosource/Invitrogen, Karlsruhe, Germany), rabbit 
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polyclonal anti-phospho-MLC2 (Thr18/Ser19) (Cell Signaling/New England Biolabs, Frankfurt a. 
M., Germany), rhodamine phalloidin (Invitrogen, Karlsruhe, Germany), Alexa Fluor 633-linked 
goat anti-mouse (Invitrogen), and Alexa Fluor 488-linked goat anti-rabbit (Invitrogen).  
Western blot analysis. HUVEC were cultured in collagen-treated 6-well plates or 60 mm-
dishes. Western blot analysis was performed as previously described (Kiemer et al., 2002a). 
The following antibodies were used: rabbit polyclonal anti-phospho-Tyr731-VE-cadherin 
(Biosource), mouse monoclonal anti-VE-cadherin (Santa Cruz), rabbit polyclonal anit-phospho-
MLC2 (Thr18/Ser19) (Cell Signaling), and MLC2 (Santa Cruz). 
 
Statistical analysis. Statistical analysis was performed with the GraphPad Prism software 
version 3.03 (GraphPad Software, San Diego, CA). Unpaired t test was used to compare two 
groups. To compare three or more groups, one-way ANOVA followed by Newman-Keuls post 
hoc test was used. 
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Results 
 
ANP protects against an inflammation-impaired endothelial barrier function in vivo. To 
judge endothelial permeability in vivo, we measured the extravasation of FITC-dextran (150 
kDa) via intravital fluorescence microscopy in postcapillary venules of the mouse cremaster 
muscle. 20 min after i.a.-application of ANP (bolus sufficient to reach 200 nM plasma 
concentration), histamine (30 !M) was superfused for 10 min. Histamine evoked a strong leak of 
FITC-dextran from the blood into the adjacent tissue. ANP clearly abrogated the histamine-
induced extravasation (Figure 1A, upper panel). Movies of this extravasation are presented as 
supplemental data (movie1: control; movie2: histamine; movie3: ANP+histamine). ANP alone (at 
least in the observed 20 min pre-treatment) seems to slightly increase basal permeability 
(please note the different ordinate scales in Figure 1A), but this effect is statistically not 
significant (Figure 1A, lower left panel). Moreover, we aimed to appraise the therapeutical 
impact of ANP by comparing its beneficial effect to that of a strong anti-inflammatory drug. Thus, 
we treated mice with a high dose of dexamethasone (i.p., 10 mg/kg, 2 h) before applying 
histamine (30 !M). The glucocorticoid completely prevented the histamine-induced 
extravasation of FITC-dextran. 
As a second approach for detecting changes of endothelial permeability in vivo, we measured 
hematocrit levels. Rats were treated with histamine (i.v. bolus sufficient to reach 1 !M plasma 
concentration) and hematocrit was determined after 30 min. Due to a reduction of plasma 
volume, i.e. augmented fluid extravasation, histamine evoked a strong hematocrit increase. 
ANP (bolus injection sufficient to reach 200 nM plasma concentration, 15 min pre-treatment) 
significantly reduced the permeability-increasing effect of histamine (Figure 1B). 
 
Characterization of the barrier protecting effect of ANP in vitro. Data about an influence of 
ANP on histamine-induced endothelial leakage in vitro are completely lacking. Thus, we first 
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aimed to verify the effect of ANP in human umbilical vein endothelial cells (HUVECs). To judge 
permeability changes, transendothelial electrical resistance (TEER) was measured. Upon 
applying histamine, the electrical resistance of a HUVEC monolayer rapidly drops within 
seconds and recovers after approx. 10 min. The extent of this effect depends on the histamine 
concentration used: the resistance is lowered to 55% by 10 !M and to 85% by 1 !M histamine 
(Figure 1C, left). ANP (1 !M, 30 min pre-treatment) attenuates the drop-down of electrical 
resistance evoked by histamine (Figure 1C, middle). The statistic analysis of all experiments (n 
= 4) performed is depicted in the right panel of Figure 1C. The large variability of the 
ANP+histamine group expresses the fact that in 2 of the 4 experiments ANP did not only 
attenuate the effect of histamine, but even increased the endothelial resistance, i.e. led to a less 
permeable endothelium, even if compared to the basal resistance under control conditions. In 
summary, ANP strongly alleviates endothelial barrier dysfunction induced by histamine in vitro. 
This warrants the usage of this system for the following investigations into the action of ANP on 
adherens junctions and the contractile machinery. 
 
ANP abolishes the histamine-evoked changes of adherens junction morphology and 
inhibits the histamine-induced VE-cadherin tyrosine phosphorylation. Histamine (1 !M) 
leads to strong changes of AJ morphology: the VE-cadherin, !-catenin, and p120ctn seam, 
properly build in untreated endothelial cells (control), becomes fringy, indicating an AJ 
disassembly, i.e. the retraction of the inter-endothelial VE-cadherin homodimers and/or an intra-
membranous lateral shift (Figure 2 A-C). Endothelial cells treated with ANP alone did not show 
any effect on AJs. Most importantly, ANP (1 !M, 30 min pretreatment) clearly abolishes the 
detrimental effects induced by histamine (Figure 2, A-C). 
To clarify which natriuretic peptide receptor is involved in mediating the beneficial actions of 
ANP, we treated cells with the NPR-A/B antagonist HS-142-1 (10 !g/ml, 10 min before ANP) 
and found that the effects on VE-cadherin disassembly were prevented by this inhibitor. The 
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NPR-C receptor agonist cANF (1 !M, 30 min before histamine) was not able to mimic the 
effects of ANP (Figure 2A). Compared to NPR-B, NPR-A binds ANP with a much higher affinity. 
Thus, our results suggest that the action of ANP is mainly transduced by NPR-A. The C-
receptor seems not to be involved. 
Phosphorylation of the VE-cadherin Tyr731 residue is associated with AJ disassembly and strong 
endothelial leakage in vitro (Potter et al., 2005). First, we verified that Tyr731 is also 
phosphorylated by histamine in vivo: Vessels of the mouse cremaster muscle show a strong 
increase of Tyr731 phosphorylation induced by histamine (30 !M, 10 min, Figure 3A) and the 
same pronounced localization at cell fringes (Figure 3A, longitudinal vessel section) as in the in 
vitro situation (Figure 3B). Most importantly, as shown both by microscopic (Figure 3B) and by 
Western blot analysis (Figure 3C), ANP completely blocked the histamine-induced VE-cadherin 
Tyr731 phosphorylation. ANP alone did not evoke any alterations of the phosphorylation (Figure 
2B). Our data clearly point towards a protecting effect of ANP on the integrity of endothelial 
adherens junctions. 
 
ANP reduces the histamine-evoked activation of myosin light chain (MLC) and the 
formation of F-actin stress fibers. The generation of contractile forces (interaction of actin and 
myosin) is governed by MLC Thr18/Ser19-phosphorylation. Histamine treatment time-dependently 
leads to a strong phosphorylation of MLC, which was analyzed microscopically (Figure 4A) and 
by Western blotting (Figure 4B). Moreover, histamine evokes a strong change in F-actin 
organization. While quiescent endothelial cells show a cortical F-actin localization, histamine 
induces the formation of long, cell-spanning stress fibers (Figure 4C). ANP clearly reduces both 
MLC phosphorylation (Figure 4, A and B) and F-actin stress fiber formation (Figure 4C). ANP 
alone had no effect on these parameters (Figure 4, A-C). These results indicate that ANP 
prevents histamine-evoked activation of the endothelial cell contraction system. 
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Furthermore, we investigated which NP receptor subtype was involved in mediating these 
effects. The NPR-A/B inhibitor HS-142-1 (10 !g/ml, 10 min before ANP) blocked the effects of 
ANP on MLC phosphorylation (Figure 4A) and stress fiber formation (Figure 4C). The NPR-C 
agonist cANF (1 !M, 30 min) was not able to show beneficial effects (Figure 4, A and C). Thus, 
NPR-A/B could be regarded as the major receptors for transducing the actions of ANP in our 
setting. 
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Discussion 
 
Many severe pathologies like sepsis or atherosclerosis are associated with an inflammation-
impaired endothelial barrier function leading to an increased plasma extravasation, and thus 
edema formation (Volk and Kox, 2000; Poredos, 2001). Proinflammatory mediators, such as 
TNF-! or histamine, are involved in the pathogenesis of these disorders and are strong inducers 
of vascular leakage. Current therapies against an inflammation-evoked barrier dysfunction (e.g. 
the administration of glucocorticoids or antihistamines) are often insufficient or even fail (van 
Nieuw Amerongen and van Hinsbergh, 2002). Therefore, new therapeutical options are needed. 
Strong progress has been made in the recent years concerning the mechanisms involved in the 
regulation of endothelial permeability (Mehta and Malik, 2006). However, substances that 
counteract an inflammation-induced vascular leakage by specifically influencing these 
mechanisms are still largely lacking (van Nieuw Amerongen and van Hinsbergh, 2002). 
Initially, the physiological action of the cardiovascular hormone ANP, i.e. the reduction of blood 
pressure, was mainly ascribed to its natriuretic, diuretic, and vasodilating action. However, ANP 
was also found to increase endothelial permeability (Huxley et al., 1987). Recently, this effect 
was proven to be crucial for the chronic control of plasma volume by ANP (Sabrane et al., 
2005). Beyond these permeability increasing effects on quiescent endothelial cells, ANP has 
increasingly been recognized to possess barrier protecting actions on an inflammation-activated 
endothelium: We could demonstrate that ANP attenuates the TNF-!-induced expression of 
adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) by inhibiting NF-"B 
activation and p38 mitogen-activated protein kinase (MAPK) signaling (Weber et al., 2003; 
Kiemer et al., 2002b). In this context, we showed that ANP protects against TNF-!-evoked 
endothelial barrier dysfunction in HUVECs (Kiemer et al., 2002a). ANP was also shown to lower 
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endothelial leakage in vitro induced by the pro-inflammatory stimuli thrombin (Baron et al., 1989) 
and VEGF (Pedram et al., 2002). 
Thus, ANP has commonly been suggested to work as a barrier protecting agent. Surprisingly, 
an obvious question has as yet not been answered precisely: Can ANP be used as 
pharmacological agent to prevent endothelial barrier dysfunction in vivo? This issue is of special 
interest, since the drug ANP (carperitide, HANP®) could open new therapeutical options for 
protecting endothelial barrier function. In the present study, we for the first time show that ANP 
administered at a pharmacological concentration is able to prevent endothelial leakage in a 
(histamine-induced) inflammatory setting in vivo. Different aspects of endothelial permeability 
were used as read-out parameters and were all beneficially influenced by ANP: macromolecular 
permeability (FITC-dextran extravasation), plasma volume/fluid changes (hematocrit), and 
electrical resistance (TEER measurement). Compared to the maximal increase of FITC-dextran 
extravasation induced by histamine (time point 45 min in Figure 1A), ANP led to approx. 65% 
reduction. Due to this pronounced effect, a therapeutical impact of ANP is not unlikely. A 
complete blockage of the deleterious effect of histamine was observed in the presence of a 
extraordinary high dosage of the glucocorticoid dexamethasone, a highly potent anti-
inflammatory drug. 
Former studies dealing with ANP and vascular permeability served as valuable hints toward an 
in vivo relevance of ANP as barrier protecting agent. However, these reports did not concisely 
test the hypothesis that administered ANP exerts beneficial effects on endothelial barrier 
dysfunction in vivo, because they (i) either used ex vivo models or (ii) focused on the 
endogenous ANP system: (i) Three older reports demonstrate that pharmacological 
concentrations of ANP attenuate changes of pulmonary wet weight induced by toxic agents like 
reactive oxygen metabolites, paraquat, or arachidonic acid in ex vivo models of isolated-
perfused lungs from rabbits or guinea pigs (Lofton et al., 1991; Inomata et al., 1987; Imamura et 
al., 1988). (ii) Blockade of endogenous ANP was shown to deteriorate pulmonary edema 
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formation in rats suffering from high altitude-induced (Irwin et al., 2001) or HCl-evoked 
(Wakabayashi et al., 1990) pulmonary vascular leakage, whereas mice lacking the major ANP-
degrading enzyme neutral endopeptidase were found to be less susceptible for pulmonary 
leakage (Irwin et al., 2005a). Interestingly, Pedram et al. showed that VEGF-induced vascular 
leakage is attenuated in ANP-overexpressing mice, whereas these mice are not protected 
against histamine-evoked leakage (Pedram et al., 2002). This might be due to the much lower 
ANP levels in these animals (plasma level: ~40 pM) compared to our setting, in which ANP is 
exogenously supplied to reach a pharmacological plasma concentration of 200 nM. Recently, 
our group could demonstrate that ANP-treated mice (plasma level: ~35 nM) are protected 
against LPS-induced septic shock (Ladetzki-Baehs et al., 2007). Since endothelial 
hyperpermeability is an important pathological feature of sepsis, it can be speculated that the 
barrier protecting effect of ANP contributes to the beneficial action in the mouse septic shock 
model. Our results suggest that pharmacological concentrations of ANP show additional, highly 
valuable effects beyond its action as an endogenous regulator of permeability. 
Adherens junctions and the contractile apparatus are key players in the regulation of endothelial 
permeability. Both the loss of VE-cadherin function and the activation of MLC result in 
decreased transendothelial electrical resistance (Garcia et al., 1997; van Buul et al., 2005) and 
increased macromolecular permeability (Nwariaku et al., 2002; Garcia et al., 1995). Studies 
investigating the action of ANP on these key systems are as yet completely lacking. We provide 
for the first time evidence that ANP interacts with these systems, since we showed that ANP 
attenuates both adherens junction disassembly (morphological changes and Tyr731 
phosphorylation of VE-cadherin) and activation of the contractile apparatus (phosphorylation of 
MLC and rearrangement of F-actin) induced by histamine. Furthermore, we could demonstrate 
that ANP exerts these effects predominantly via the natriuretic peptide receptor (NPR)-A. Since 
this receptors represent particulate guanylate cyclases, it can be speculated that the actions of 
ANP might be mediated via the second messenger cyclic guanosine monophosphate (cGMP). 
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Our results add further support to the hypothesis that ANP is an endothelium protecting agent, 
since it directly counteracts the detrimental effects of proinflammatory mediators on endothelial 
barrier function.  
Only few data exist about the action of ANP on subcellular systems contributing to permeability 
regulation. We and others could demonstrate that ANP inhibits F-actin stress fiber formation 
induced by TNF-! (Kiemer et al., 2002a; Irwin et al., 2005b) or VEGF (Pedram et al., 2002). 
Interestingly, one study reports that ANP influences tight junctions in bovine aortic endothelial 
cells (Pedram et al., 2002). In contrast to the dense aortic endothelium, the occurrence of tight 
junctions is limited in the venous endothelium (Ogunrinade et al., 2002), which represents the 
predominant site of endothelial hyperpermeability and was investigated in the present study. 
In summary, we have revealed ANP as a potent endothelial barrier protecting agent in vivo. 
Moreover, we have identified adherens junctions and the contractile apparatus as important 
subcellular systems targeted by ANP. Most importantly, our study highlights ANP as an 
interesting pharmacological compound opening a new therapeutic option for the prevention of 
vascular leakage. This warrants further efforts aiming for an expansion of the therapeutic 
indications of natriuretic peptides. 
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Figure 1. ANP attenuates histamine-induced increase of endothelial permeability in vivo and in 
vitro. 
A, Extravasation of FITC-dextran (150 kDa) from venules of the mouse cremaster muscle was 
measured. Upper left panel: Mice were pre-treated with Ringer solution (control and histamine 
group), or with ANP (i.a. bolus injection sufficient to reach 200 nM plasma concentration). After 
20 min, histamine (30 !M) was superfused for 10 min (histamine and ANP+histamine group). 
Data are expressed as mean ± SEM (n = 6). *p"0.05 vs. histamine. Upper right panel: One 
representative image is shown for each group of treatment (at time point 45 min for control, 
histamine, and histamine+ANP; at time point 30 min for ANP alone). Videos showing this FITC-
dextran extravasation (movie1: control; movie2: histamine; movie3: ANP+histamine) are 
available as supplemental data. Lower left panel: Mice were treated with Ringer solution (control 
group) or with ANP (i.a. bolus injection sufficient to reach 200 nM plasma concentration). Data 
are expressed as mean ± SEM (n = 6). Lower right panel: Mice were pre-treated with Ringer 
solution (histamine group) or with dexamethasone (i.p., 10 mg/kg bodyweight) for 2 h. Histamine 
(30 !M) was superfused for 10 min. Data are expressed as mean ± SEM (n = 2). 
B, Plasma volume changes were determined by measuring hematocrit values. Rats were pre-
treated with PBS (control) or with ANP (i.v., bolus injection sufficient to reach 200 nM plasma 
concentration). After 15 min, histamine was applied (i.v., bolus injection sufficient to reach 1 !M 
plasma concentration). 30 min later, blood samples were taken and hematocrit was measured. 
Data are expressed as mean ± SEM (n = 3). *p"0.05 vs. histamine. 
C, Transendothelial electrical resistance (TEER) was used to judge changes in endothelial 
permeability of HUVECs. Left panel: Histamine concentration-dependently decreases TEER 
values. Middle panel: ANP (1 !M, 30 min pre-treatment) attenuates the histamine-induced 
decrease of electrical resistance. One representative graph out of 4 independent experiments is 
shown, each. Right panel: Statistical analysis of all experiments performed (n = 4). Data are 
expressed as mean ± SEM. *p"0.05 vs. histamine. 
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Figure 2. ANP inhibits the histamine-evoked morphological changes of adherens junctions. 
HUVECs were left untreated (control) or were treated with histamine (1 !M, 2 min) alone or in 
combination with ANP (1 !M, 30 min pre-treatment) or the NPR-C agonist cANF (1 !M, 30 min 
pre-treatment). The NPR-A/B receptor antagonist HS142-1 (10 !g/ml) was given 10 min before 
ANP. Immunocytochemistry and confocal fluorescence microscopy were performed to analyze 
ANP 116 
 
 
morphological changes of (A) VE-cadherin, (B) !-catenin, and (C) p120ctn. One representative 
image out of three independent experiments is shown, each. 
                
Figure 3. ANP blocks histamine-induced VE-cadherin Tyr731-phosphorylation. A, Histamine 
induces phosphorylation of VE-cadherin at Tyr731 in vivo. Mice were treated as described in 
Figure 1A. Samples of the mouse cremaster muscle were analyzed via immunohistochemistry 
and confocal fluorescence microscopy. Histamine (30 !M) was superfused for the indicated 
times. One representative image out of 3 independent experiments is shown. B-C, ANP inhibits 
histamine-induced VE-cadherin Tyr731-phosphorylation in vitro. HUVECs were left untreated 
(control), were treated with histamine 
(1 !M, 5 min) or ANP (1 !M, 30 min) alone, or with ANP (1 !M) 30 min before histamine was 
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applied. The VE-cadherin Tyr731-phosphorylation was analyzed via immunocytochemistry and 
confocal fluorescence microscopy (B, n = 3) or biochemically via Western blot (C, n = 2). 
          
Figure 4. ANP inhibits histamine-induced MLC2 Thr18/Ser19-phosphorylation and stress fiber 
formation. A-C, HUVECs were left untreated (control) or were treated with histamine (1 !M, 5 
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min) alone or in combination with ANP (1 !M, 30 min pre-treatment) or the NPR-C agonist cANF 
(1 !M, 30 min pre-treatment). The NPR-A/B receptor antagonist HS142-1 (10 !g/ml) was given 
10 min before ANP. MLC2 Thr18/Ser19-phosphorylation and F-actin were analyzed via 
immunocytochemistry and confocal fluorescence microscopy (A, C). MLC2 Thr18/Ser19-
phosphorylation was additionally analyzed via Western blot (B). One representative image out 
of at least three independent experiments is shown, each. 
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VIII  APPENDIX 
1 Abbreviations 
 
8-Bromo-cAMP 8-Bromoadenosine-3´,5´-cyclic 
monophosphate 
AC adenylate cyclase 
AJ adhesion junction 
AP1 activator protein-1 
Cell Signaling Cell Signaling Technology® 
CAM cell adhesion molecule 
cAMP cyclic adenosine 3´,5´-monophosphate 
cAMPS-Rp (R)-Adenosine, cyclic 3´5´-
(hydrogenphosphorothioate) 
triethylammonium salt 
CHF chronic heart failure 
DAG diacylglycerol 
DMSO dimethyl sulfoxide 
DTT dithio-1,4-threitol  
EC endothelial cell 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
EHP endothelial hyperpermeability 
Epac-1 exchange proteins directly activated by 
cAMP-1 
Epac-cAMP/8-pCPT-2´-O-Me-cAMP 8-( 4- Chlorophenylthio)-2´-O- 
methyladenosine-3`, 5`- cyclic 
monophosphat  
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FURA-2, AM Ester Fura-2-pentakis(acetoxymethyl) ester 
HEPES N-(2-hydroxyethyl)piperazine-N’-(2-
ethanesulfonic acid)  
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HMEC  human microvascular epithelial cell 
HUVEC humen umbilian vain endothelial cell  
ICAM intercellular adhesion molecule 
IP3 inositol triphospath  
MLC2  myosin light chain 2 
MLCK myosin light chain kinase 
MLCP myosin light chain phosphatase 
NF-κB nuclear factor kappa-light-chain-enhancer of 
activated B cells 
PBS phosphate-buffered saline 
PDE phosphodiesterase 
PIP2 phasphatidylinositol-4,5-bisphosphate 
PKC protein kinase C 
PKA protein kinase A 
PMSF phenylmethylsulfonylfluorid 
phos. phosphorylated 
Rac1 Ras-related C3 botulinum toxin substrate 1 
Rap1 Ras-proximate-1 
RhoA Ras homolog gene family, member A  
ROC receptor-operated Ca2+ channel 
Santa Cruz Santa Cruz Biotechnology 
SOC store-operated Ca2+ channel 
STAT-1 signal transducers and activator of 
transcription protein-1   
sub. substrate  
TNFα tumor necrosis factorα 
VASP vasodilator-stimulated phosphoprotein  
VEC vascular endothelial cadherin 
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2 Publications 
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